What changed in this filing

/stocks — the workspaceLOADING

Item 1A. Risk Factors

2026-03-25 compared with 2025-03-26 · 1177 added, 481 removed, 30 unchanged (98% of the section changed)

Investing in our common stock involves a high degree of risk.

You should carefully consider the following material risks, together with the other matters described in this Annual Report and in our financial statements and the related notes thereto in evaluating our current business and future performance.

in our common stock involves a high degree of risk.

You should carefully consider the following material risks, together with the other

matters described in this Annual Report and in our financial statements and the related notes thereto in evaluating our current business

and future performance.

We cannot assure you that any of the events discussed in the risk factors below will or will not occur.

If we are not able to successfully address any of the following risks, we could experience significant changes in our business, operations and financial performance.

In such circumstances, the trading price of our common stock could decline, and in some cases, such declines could be significant, and you could lose part or all of your investment.

In addition to the risks described below, other unforeseeable risks that we currently believe are immaterial may arise that adversely affect our operating results.

Certain statements contained in this Annual Report (including certain statements used in the discussion of our risk factors) constitute forward-looking statements.

Please refer to the section entitled “ Cautionary Note Regarding Forward-Looking Statements ” for important information regarding reliance on forward-looking statements.

Risks Related to Our Business and Financial Condition

We may not succeed in implementing our business strategy.

As we attempt to adapt our microbial protein production platforms, including C1 and Dapibus™ and our other technologies for use in the biopharmaceutical and other markets, our business is subject to the execution, integration, and research and development risks that early-stage companies customarily face with new technologies, products and markets.

These risks relate to, among other things, our ability to successfully further develop our protein production platforms and our other technologies, products and processes, assemble and maintain adequate production and research and development (“R&D”) capabilities, comply with regulatory requirements, construct effective channels of distribution and manage growth.

We have encountered and will continue to encounter risks and difficulties frequently experienced by early-stage companies in expanding and upgrading our intellectual property, regulatory, marketing, sales and R&D capabilities, improving our accounting and financial reporting and internal controls infrastructure, and adapting to the rapidly evolving industries in which we operate.

Additionally, we are subject to competition from much larger companies with more resources than we have.

Also, the market for developing and manufacturing pharmaceutical proteins produced from a filamentous fungus, such as the C1 fungus, is a market that is not yet established and is subject to a high level of regulatory hurdles from the U.S.

Food and Drug Administration (the “FDA”) and other governmental bodies, and there is a risk that such technologies will not be adopted by the pharmaceutical industry or governmental agencies and therefore not succeed and/or not grow at the rates projected or at all.

We have not yet commercialized any products based on our platforms and technologies, and we may never be able to do so.

We do not know when or if we and/or our current and/or future collaborators and licensees will complete any of our or their product development efforts, obtain regulatory approval for any product candidates incorporating our technologies or successfully commercialize any approved products.

Even if we and/or our licensees and collaborators are successful in developing products that are approved for marketing, we and they will still require that these products gain regulatory approval and market acceptance.

The biopharmaceutical industries in which we operate are high-risk industries in that even if we are successful at expressing certain proteins, these proteins may fail to be advanced or approved for use or sale for many reasons including their characteristics, biological activity, biological comparability, biological similarity, stability, glycosylation structures, containments, purity, performance, safety and regulatory reasons.

Because of the numerous risks and uncertainties associated with pharmaceutical and other product development, we are unable to predict the timing or amount of increased expenses or when, or if, we will be able to achieve certain technology, product and/or commercial milestones, access fees and royalties, launch products and/or processes, or achieve profitability.

For instance, we cannot predict whether Danisco intends to or will pursue the use of the C1 platform to develop or manufacture pharmaceutical products or whether or when we might receive royalties from Danisco.

In addition, our expenses could increase if we are required by the FDA or other domestic and foreign regulatory authorities to perform studies or trials in addition to those currently expected, or if there are delays in completing additional safety studies such as toxicology and pathogenicity studies, clinical trials, preclinical studies, animal or human studies or the development of any of our or our collaborators’ product candidates.

A significant portion of our revenue is derived from a small number of customers.

For the years ended December 31, 2024 and 2023, the Company’s revenue was generated from 19 and 16 customers, respectively.

As of December 31, 2024 and 2023, the Company’s accounts receivable was from nine and thirteen customers, respectively.

Significant customers are those that account for greater than 10% of the Company’s revenues.

For the years ended December 31, 2024 and 2023, two significant customers accounted for approximately $1,915,000 or 54.8% and $1,503,000 or 51.9% of revenue, respectively.

We cannot assure you that these customers will continue to contract with us on terms currently in effect or other terms which are favorable but not currently in effect, or whether they will elect to contract with our competitors or attempt to perform the services themselves.

The loss of business from one or a combination of the Company’s customers, if not offset by revenue from new or other existing customers, or any inability of any customer to pay amounts as and when due, could adversely affect its operations.

We have a history of net losses, and we may not achieve or maintain profitability.

As of December 31, 2024, we had an accumulated deficit of approximately $86.1 million.

Our profitability has strongly relied on, and will be even more reliant going forward on, third-party industry and government research funding, licensing partnerships and other forms of collaborations.

We believe that it is likely that if we do not sign license agreements or other forms of collaborations, we will incur losses because of our planned levels of R&D and additional general and administrative expenditures that we believe are necessary to operate our business and further develop our microbial protein production platforms and other technologies for use in the pharmaceutical and non-pharmaceutical industries.

The amount of our future net losses will depend, in part, on the rate of increase in our expenses along with other potential costs of unforeseen circumstances, our ability to generate research funding, government grants, receipt of access fees, milestones, royalty and other payments, and whether we are able to generate revenues by entering into license agreements or other forms of collaborations, launch new products and/or processes from future licensees or collaborators, and our ability to raise additional capital.

The net losses we anticipate incurring over the next several years will have an adverse effect on our working capital, financial condition, results of operations and prospects.

The R&D efforts needed to enhance and leverage our microbial protein production platforms, including C1 and Dapibus™, for use in developing and manufacturing human and animal biopharmaceuticals and other non-pharmaceutical products will require significant funding and increased staffing.

Therefore, we expect near-term operating and research expenses to continue, and maybe even accelerate, as we further develop our research and business plans, and our goals and objectives.

Consequently, we will require significant additional revenue to achieve profitability.

We cannot provide assurance that we will be able to generate any revenues from our focus and efforts as we intend to apply our C1-cell and Dapibus™ into the biopharmaceutical and non-pharmaceutical industries.

If we fail to enter into new license agreements or other forms of collaborations or generate revenues and profit from additional research projects and government grants, the market price of our common stock will likely decrease.

Further regulatory complications, competition from other technologies, or delays in our research programs and the adoption and use of the C1-cell and Dapibus™ protein production platforms and our other technologies by the biopharmaceutical and non-pharmaceutical industries may force us to reduce our staffing and research and development efforts, which may further affect our ability to generate cash flow.

We may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable or for which there is a greater likelihood of success.

As a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates to pursue and may forego or delay pursuit of opportunities with other targets or product candidates that later prove to have greater commercial potential.

Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.

Failure to properly assess potential product candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition, results of operations and prospects.

Our spending on current and future R&D programs and product candidates may not yield any commercially viable products.

Our understanding and evaluation of biological targets for the discovery and development products expressed from C1 may fail to identify challenges encountered in subsequent preclinical and clinical development.

If we do not accurately evaluate the likelihood of clinical trial success, commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights.

We could fail to manage our growth.

We will need to take the following steps, among others, to manage our growth.

If we fail to achieve one or more of these, it could have a material adverse effect on our business, financial condition and results of operations.

Balance our cash burn with technology and product development;

Maintain and add additional CROs, other third-party service providers or other technology collaborators;

Maintain and add additional collaborators, strategic partners technology licensees or other forms of structures

Recruit, hire, and maintain the required employees necessary to maintain and grow our business and to advance our technologies and products;

Achieve technical and commercial success in our research and product development programs;

Manage our internal development and operational efforts effectively while carrying out our contractual obligations to third parties;

Access required manufacturing capacity;

are not able to successfully address any of the following risks, we could experience significant changes in our business, operations

and financial performance.

In such circumstances, the trading price of our common stock could decline, and in some cases, such declines

could be significant, and you could lose part or all of your investment.

In addition to the risks described below, other unforeseeable

risks that we currently believe are immaterial may arise that adversely affect our operating results.

Certain statements contained in

this Annual Report (including certain statements used in the discussion of our risk factors) constitute forward-looking statements.

refer to the section entitled “ Cautionary Note Regarding Forward-Looking Statements ” for important information

regarding reliance on forward-looking statements.

Related to Our Business and Financial Condition

may not succeed in implementing our business strategy.

recently launched a strategic plan to transition from a research-driven organization to a commercially focused enterprise, with an emphasis

on delivering applied biotechnology solutions through our C1 and Dapibus™ technologies for use in the biopharmaceutical and other

Our focus is to commercialize high-value, non-therapeutic proteins in the life sciences, food, nutrition and industrial bioprocessing

This strategic shift involves significant risks and uncertainties.

Our success will depend on our ability to further develop

and scale our protein production platforms, establish manufacturing, quality and commercial capabilities, construct effective channels

of distribution, achieve market acceptance, manage growth, and compete effectively against larger, better-capitalized companies.

non-therapeutic proteins typically face fewer regulatory hurdles than therapeutic biologics, products incorporating our technologies

may still be subject to regulatory review, quality standards, and customer qualification requirements, and market adoption of proteins

produced using filamentous fungi such as the C1 fungus is not yet fully established.

Additionally,

our business remains subject to the execution, integration, and research and development risks with respect to new technologies, products

These risks relate to, among other things, our ability to successfully further develop our protein production platforms

and our other technologies, products and processes, assemble and maintain adequate production and research and development (“R&D”)

capabilities.

We have encountered and will continue to encounter risks and difficulties frequently experienced by early-stage companies

in expanding and upgrading our intellectual property, regulatory, marketing, sales and R&D capabilities, improving our accounting

and financial reporting and internal controls infrastructure, and adapting to the rapidly evolving industries in which we operate.

market for developing and manufacturing pharmaceutical proteins produced from a filamentous fungus, such as the C1 fungus, is a market

that is not yet established and is subject to regulatory hurdles from the U.S.

Food and Drug Administration (the “FDA”) and

other governmental bodies, and there is a risk that such technologies will not be adopted by the pharmaceutical industry or governmental

agencies and therefore not succeed and/or not grow at the rates projected or at all.

Further, public perception may be influenced by

claims that filamentous fungus is unsafe or ineffective, and these fungi may not gain the acceptance of the public or the medical community.

More restrictive regulations or negative public perception could reduce certain of our customers’ use of our products, which could

negatively affect our future revenues and performance.

have not yet commercialized any products based on our platforms and technologies, and we may never be able to do so.

We do not know

when or if we and/or our current and/or future collaborators and licensees will complete any of our or their future product

development efforts, obtain regulatory approval for any future product candidates incorporating our technologies or successfully

commercialize any approved products.

Even if we and/or our licensees and collaborators are successful in developing future products

that are approved for marketing, we and they will still require that these products gain regulatory approval and market acceptance.

The biopharmaceutical, life sciences, food, nutrition and industrial bioprocessing industries in which we or our collaborators

operate are high-risk industries in that even if we are successful at expressing certain proteins, these proteins may fail to be

advanced or approved for use or sale for many reasons including their characteristics, biological activity, biological

comparability, biological similarity, stability, glycosylation structures, containments, purity, performance, safety and regulatory

Relatedly, the U.S.

government’s plans to regulate lab developed tests may impact the customers and industries we

serve by increasing the cost of commercializing and/or limiting the profitability of commercialized products.

of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of

increased expenses or when, or if, we will be able to achieve certain technology, product and/or commercial milestones, access fees

and royalties, launch products and/or processes, or achieve profitability.

For instance, we cannot predict whether Danisco intends

to or will pursue the use of the C1 platform to develop or manufacture pharmaceutical products or whether or when we might receive

royalties from Danisco.

In addition, if the FDA or other regulatory authorities impose additional requirements that may lead to delays or

unfavorable results in completing required safety and regulatory submissions, including Generally Recognized as Safe (“GRAS”),

determinations or similar filings, our business operations and financial condition may be adversely affected.

significant portion of our revenue is derived from a small number of customers.

the years ended December 31, 2025 and 2024, the Company’s revenue was generated from 14 and 19 customers, respectively.

As of December 31,

2025 and 2024, the Company’s accounts receivable was from four and nine customers, respectively.

Significant customers are those

that account for greater than 10% of the Company’s revenues.

For the years ended December 31, 2025 and 2024, two significant customers

accounted for approximately $1,859,000 or 60.1% and $1,915,000 or 54.8% of revenue, respectively.

We cannot assure you that these customers

will continue to contract with us on terms currently in effect or other terms which are favorable but not currently in effect, or whether

they will elect to contract with our competitors or attempt to perform the services themselves.

The loss of business from one or a combination

of the Company’s customers, if not offset by revenue from new or other existing customers, or any inability of any customer to pay

amounts as and when due, could adversely affect its operations.

have a history of net losses, and we may not achieve or maintain profitability.

of December 31, 2025, we had an accumulated deficit of approximately $93.5 million.

Our profitability has strongly relied on, and

will be even more reliant going forward on, third-party industry and government research funding and grants, licensing partnerships and other

forms of collaborations.

We believe that it is likely that if we do not sign license agreements or other forms of collaborations, we

will incur losses because of our planned levels of R&D and additional general and administrative expenditures that we believe

are necessary to operate our business and further develop our microbial protein production platforms and other technologies for use

in the pharmaceutical and non-pharmaceutical industries.

The amount of our future net losses will depend, in part, on the rate of

increase in our expenses along with other potential costs of unforeseen circumstances, our ability to generate research funding,

government grants, receipt of access fees, milestones, royalty and other payments, and whether we are able to generate revenues by

entering into license agreements or other forms of collaborations, launch new products and/or processes from future licensees or

collaborators, and our ability to raise additional capital.

The net losses we anticipate incurring over the next several years will

have an adverse effect on our working capital, financial condition, results of operations and prospects.

strategic efforts as part of our rebranding and R&D efforts needed to enhance and leverage our microbial protein production platforms,

including C1 and Dapibus™, for use in developing and manufacturing human and animal biopharmaceuticals and other non-pharmaceutical

products will require significant funding and increased staffing.

Therefore, we expect near-term operating and research expenses to continue,

and maybe even accelerate, as we further develop our research and business plans, and our goals and objectives.

Consequently, we will

require significant additional revenue to achieve profitability.

We cannot provide assurance that we will be able to generate any revenues

from our focus and efforts as we intend to apply our C1-cell and Dapibus™ into the biopharmaceutical and non-pharmaceutical industries.

If we fail to enter into new license agreements or other forms of collaborations or generate revenues and profit from additional research

projects and government grants, the market price of our common stock will likely decrease.

Further regulatory complications, competition

from other technologies, or delays in our research programs and the adoption and use of the C1-cell and Dapibus™ protein production

platforms and our other technologies by the biopharmaceutical and non-pharmaceutical industries may force us to reduce our staffing and

research and development efforts, which may further affect our ability to generate cash flow.

may expend our resources to pursue particular product candidates and fail to capitalize on product candidates that may be more profitable

or for which there is a greater likelihood of success.

a result of our limited financial and managerial resources, we must make strategic decisions as to which targets and product candidates

to pursue and may forego or delay pursuit of opportunities with other targets or product candidates that later prove to have greater

commercial potential, including our transition to being a commercially driven enterprise.

Our resource allocation decisions may cause

us to fail to capitalize on viable commercial products or profitable market opportunities.

Failure to properly assess potential product

candidates could result in our focus on product candidates with low market potential, which would harm our business, financial condition,

results of operations and prospects.

Our spending on current and future R&D programs and product candidates may not yield any commercially

viable products.

Our and our collaborators’ and licensees’ understanding and evaluation of biological targets for the discovery and development

of products expressed from our C1 and/or Dapibus platforms may prove to be incorrect or incomplete and may fail to identify risks, safety

concerns, or other challenges that could arise during subsequent GRAS determinations or similar filings.

If we or our collaborators or

licensees do not accurately assess the likelihood of clinical trial success, regulatory approval, commercial potential, or target market

for a particular product candidate our business operations and financial condition would be materially and adversely affected.

could fail to manage our growth.

will need to take the following steps, among others, to manage our growth.

If we fail to achieve one or more of these, it could have

a material adverse effect on our business, financial condition and results of operations.

Balance our cash burn with

technology and product development;

and add additional CROs, other third-party service providers or other technology collaborators;

Maintain and add additional

collaborators, strategic partners technology licensees or other forms of structures

Recruit, hire, and maintain

the required employees necessary to maintain and grow our business and to advance our technologies and products;

Achieve technical and commercial

success in our research and product development programs;

Develop and scale our infrastructure;

Manage our internal development

and operational efforts effectively while carrying out our contractual obligations to third parties;

Manage unanticipated problems

delays and expenses relating to the development and implementation of our new business plans;

Access required manufacturing

Access additional capital;

Recruit and maintain consultants, board members, and scientific advisory board members;

Manage scientific risks and uncertainties that may arise during our R&D and regulatory programs.

Our revenue growth depends in part on market and regulatory acceptance of our microbial protein production platforms and other technologies to develop and manufacture animal and/or human biopharmaceutical and non-pharmaceutical products.

The success of our business will depend on our ability to develop, register, and introduce similar, new and improved technologies and products in a timely manner, at significantly lower manufacturing costs that address the evolving requirements of the relevant industries and potential customers.

There is no assurance that the C1 platform or any product expressed from C1, or our other technologies, will perform the same or better or save our customers money relative to existing gene expression technologies or those of our competitors, obtain governmental safety and regulatory approvals, be registered or gain market acceptance.

If we fail to develop similar, new and better performing technologies, products and processes at significantly lower manufacturing costs, make fermentation yield improvements on our existing production processes, generate the necessary safety and regulatory data or gain registration and market acceptance of the C1-cell and Dapibus™ protein production platforms, or our other technologies, products or processes, we could fail to recoup our R&D investments and fail to capitalize on potential opportunities or gain market share from our competitors.

Any failure, for technological, quality, safety, regulatory, or other reasons, to develop and launch improved technologies and new products, could negatively impact our business, financial condition and results of operation.

The dynamic and conservative nature of the industries in which we operate, the unpredictable nature of the product development process and the time and cost of new technology adoption in the industries in which we operate may affect our ability to meet the requirements of the marketplace or achieve market and/or regulatory acceptance.

The expenses or losses associated with unsuccessful technology and product development activities or lack of market acceptance of our new technologies and products could harm our business, financial condition and results of operations.

We may fail to commercialize our microbial protein production platforms or other technologies for the expression of therapeutic proteins, antibodies, vaccines, and metabolites or other non-pharmaceutical biologic products.

We have not yet completed the necessary safety, efficacy, cost and regulatory studies, or the commercialization of any therapeutic proteins, antibodies and vaccines, and metabolites or other non-pharmaceutical biologic products based on C1 or Dapibus™.

To date, drug companies have developed and commercialized only a small number of gene-based products in comparison to the total number of drug molecules available in the marketplace.

Our biopharmaceutical business should be evaluated as having the same risks as those inherent to early-stage biotechnology companies because the application of the C1 platform for the expression of pre-clinical and clinical quantities of therapeutic proteins, antibodies and vaccines is still in early development.

Successful development of our microbial protein production platforms, including C1 and Dapibus™, for biopharmaceutical and non-pharmaceutical purposes will require significant research, development and capital investment, including testing, to prove its safety, efficacy and cost-effectiveness.

In general, our experience has been that each step in the process has been longer and costlier than originally projected, and we anticipate that this is likely to remain the case with respect to the continuing development efforts of our biopharmaceutical and non-pharmaceutical business.

If our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial opportunity will be reduced or eliminated.

The industries in which we operate are characterized by rapid technological change, and the area of gene and protein research and platform development is a rapidly evolving field.

We believe that a significant number of products are currently under development, and may become commercially available in the future, for the issues and conditions for which we are developing product candidates.

As such, any products we or our current collaborators or licensees develop through the C1 platform, or through our other technologies, will compete in highly competitive and regulated markets.

Recruit and maintain consultants,

board members, and scientific advisory board members;

scientific risks and uncertainties that may arise during our R&D and regulatory programs.

revenue growth depends in part on market and regulatory acceptance of our microbial protein production platforms and other technologies

to develop and manufacture animal and/or human biopharmaceutical and non-pharmaceutical products.

success of our business will depend on our ability to develop, register, and introduce similar, new and improved technologies and products

in a timely manner, at significantly lower manufacturing costs that address the evolving requirements of the relevant industries and

potential customers.

There is no assurance that the C1 platform or any product expressed from C1, or our other technologies, will perform

the same or better or save our customers money relative to existing gene expression technologies or those of our competitors, obtain

governmental safety and regulatory approvals, be registered or gain market acceptance.

If we fail to develop similar, new and better

performing technologies, products and processes at significantly lower manufacturing costs, make fermentation yield improvements on our

existing production processes, generate the necessary safety and regulatory data or gain registration and market acceptance of the C1-cell

and Dapibus™ protein production platforms, or our other technologies, products or processes, we could fail to recoup our R&D

investments and fail to capitalize on potential opportunities or gain market share from our competitors.

Any failure, for technological,

quality, safety, regulatory, or other reasons, to develop and launch improved technologies and new products, could negatively impact

our business, financial condition and results of operation.

dynamic and conservative nature of the industries in which we operate, the unpredictable nature of the product development process and

the time and cost of new technology adoption in the industries in which we operate may affect our ability to meet the requirements of

the marketplace or achieve market and/or regulatory acceptance.

expenses or losses associated with unsuccessful technology and product development activities or lack of market acceptance of our new

technologies and products could harm our business, financial condition and results of operations.

may fail to commercialize our microbial protein production platforms or other technologies for the expression of therapeutic proteins,

antibodies, vaccines, and metabolites or other non-pharmaceutical biologic products.

have not yet completed the necessary safety, efficacy, cost and regulatory studies, or the commercialization of any therapeutic proteins,

antibodies and vaccines, and metabolites or other non-pharmaceutical biologic products based on C1 or Dapibus™.

date, drug companies have developed and commercialized only a small number of gene-based products in comparison to the total number of

drug molecules available in the marketplace.

Our biopharmaceutical business should be evaluated as having the same risks as those inherent

to early-stage biotechnology companies because the application of the C1 platform for the expression of pre-clinical and clinical quantities

of therapeutic proteins, antibodies and vaccines is still in early development.

development of our microbial protein production platforms, including C1 and Dapibus™, for biopharmaceutical and non-pharmaceutical

purposes will require significant research, development and capital investment, including testing, to prove its safety, efficacy and

cost-effectiveness.

In general, our experience has been that each step in the process has been longer and costlier than originally projected,

and we anticipate that this is likely to remain the case with respect to the continuing development efforts of our biopharmaceutical

and non-pharmaceutical business.

our competitors develop technologies and products more quickly and market more effectively than our product candidates, our commercial

opportunity will be reduced or eliminated.

industries in which we operate are characterized by rapid technological change, and the area of gene and protein research and platform

development is a rapidly evolving field.

We believe that a significant number of products are currently under development, and may become

commercially available in the future, for the issues and conditions for which we are developing product candidates.

As such, any products

we or our current collaborators or licensees develop through the C1 platform, or through our other technologies, will compete in highly

competitive and regulated markets.

For more information on our competition, see “Item 1.

Business—Competition.” Many of these competitors for such products have more capital resources, larger R&D and marketing staff, facilities and capabilities, and greater experience in research and development, regulatory approval, manufacturing and commercialization of technology and products.

Accordingly, our competitors may be able to develop technologies and products more rapidly.

Our future success will depend on our ability to maintain a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity and cost.

If a competitor develops superior technology or products, or more cost-effective alternatives to our and our collaborators’ or licensees’ technologies, products or processes, it could have a material adverse effect on our business, financial condition and results of operations.

Well-known and highly competitive biotechnology companies offer comparable or alternative technologies for the same products and services as our biopharmaceutical and non-pharmaceutical business.

We anticipate that we and our current or future collaborators and licensees will continue to encounter increased competition as new companies enter these markets and as the development of biological processes and products evolves, and there is no guarantee that our product candidates will be able to compete with potential future products being developed by competitors.

Alternative technologies may not require microbial or other cell produced proteins, such as our proprietary C1 cells.

Research is being conducted with cell or gene-based therapies and other technologies that offer a possible alternative to producing proteins as they are being produced today based on microbial, organic matter containing carbon, hydrogen, and oxygen or other organisms, such as our proprietary C1 cells or Dapibus™.

Alternative methods may allow genes to be directly inserted into cells that can be implanted into animals and humans directly, displacing the need for the existing methods used for the development of biologic vaccines and drugs.

If they are successful, these new methods may supplant or greatly reduce the need for microorganisms, carbon, hydrogen, and oxygen or other organisms, including our C1 cells and Dapibus™, to produce these proteins externally as the injected cells in animals and humans may be able to do so internally.

The results of nonclinical studies and early-stage clinical trials may not be predictive of future results.

The results of nonclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage clinical trials we commence may not be predictive of the results of the later-stage clinical trials.

Vaccine and drug candidates in later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical studies and initial clinical trials.

There is a high failure rate for drugs proceeding through clinical trials, and a number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies.

There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our vaccine and drug candidates.

Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval of any products.

Any such setbacks in our clinical development could have a material adverse effect on our business and operating results.

We may need substantial additional capital in the future to fund our business.

Our future capital requirements may be substantial, particularly as we continue to further develop, engineer and optimize our microbial protein production platforms and other proprietary technologies, products and processes for licensing for research and development, and commercialization of potential animal and human pharmaceutical and other products.

We currently have very little leverage, and if our capital resources are insufficient to meet our capital requirements, we will have to raise additional funds to continue the development of our technologies and complete the development and commercialization of products, if any, resulting from our technologies.

If the acquisition of additional funds is not possible or if we engage in future equity financings, dilution to our existing stockholders may result.

If we raise capital through debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business.

Also, to the extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be further dilution to investors and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders’ rights.

Business-Competition.” Many of these

competitors for such products have more capital resources, larger R&D and marketing staff, facilities and capabilities, and greater

experience in research and development, regulatory approval, manufacturing and commercialization of technology and products.

our competitors may be able to develop technologies and products more rapidly.

Our future success will depend on our ability to maintain

a competitive position with respect to technological advances in terms of product and process quality, stability, safety, productivity

If a competitor develops superior technology or products, or more cost-effective alternatives to our and our collaborators’

or licensees’ technologies, products or processes, it could have a material adverse effect on our business, financial condition

and results of operations.

Well-known and highly competitive biotechnology companies offer comparable or alternative technologies for

the same products and services as our biopharmaceutical and non-pharmaceutical business.

We anticipate that we and our current or future

collaborators and licensees will continue to encounter increased competition as new companies enter these markets and as the development

of biological processes and products evolves, and there is no guarantee that our product candidates will be able to compete with potential

future products being developed by competitors.

technologies may not require microbial or other cell produced proteins, such as our proprietary C1 cells.

is being conducted with cell or gene-based therapies and other technologies that offer a possible alternative to producing non-therapeutic

proteins as they are being produced today based on microbial, organic matter containing carbon, hydrogen, and oxygen or other organisms,

such as our proprietary C1 cells or Dapibus™.

Alternative methods may allow genes to be directly inserted into cells that can be

implanted into animals and humans directly, displacing the need for the existing methods used for the development of our non-therapeutic

technologies.

If they are successful, these new methods may supplant or greatly reduce the need for microorganisms, carbon, hydrogen,

and oxygen or other organisms, including our C1 cells and Dapibus™, to produce these proteins externally as the injected cells

in animals and humans may be able to do so internally.

results of nonclinical studies and early-stage clinical trials may not be predictive of future results.

results of our nonclinical studies may not be predictive of the results of clinical trials, and the results of any early-stage

clinical trials we commence may not be predictive of the results of the later-stage clinical trials.

Vaccine and drug candidates in

later stages of clinical trials may fail to show the desired safety and efficacy despite having progressed through nonclinical

studies and initial clinical trials.

In addition, results from early development work may not be predictive of outcomes in

subsequent regulatory processes, including GRAS determinations or similar notifications, or other domestic and foreign regulatory

There is a high failure rate for drugs proceeding through clinical trials, and a number of companies in the pharmaceutical

and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in

earlier studies.

There can be no assurance that any of our current or future clinical trials will ultimately be successful or

support further clinical development of any of our vaccine and drug candidates.

Even if our clinical trials are completed, the

results may not be sufficient to obtain regulatory approval of any products.

Any such setbacks in our clinical development could

have a material adverse effect on our business and operating results.

may need substantial additional capital in the future to fund our business.

future capital requirements may be substantial, particularly as we continue to further develop, engineer and optimize our microbial protein

production platforms and other proprietary technologies, products and processes for licensing for research and development, and commercialization

of potential animal and human pharmaceutical and other products.

currently have very little leverage, and if our capital resources are insufficient to meet our capital requirements, we will have to

raise additional funds to continue the development of our technologies and complete the development and commercialization of

products, if any, resulting from our technologies.

For example, in August 2025, we completed an underwritten offering of our common

stock for net proceeds of $4.9 million.

There can be no assurances that additional funds will be available, and if we engage in

future equity financing, dilution to our existing stockholders may result, including as a result of our ATM Program (as defined below).

If we raise capital

through debt financing, we may be subject to restrictive covenants that limit our ability to conduct our business.

extent we raise additional capital through the issuance of equity or convertible debt securities in the future, there will be

further dilution to investors, and the terms of these securities may include liquidation or other preferences that adversely affect

our stockholders’ rights.

We may not be able to raise funds on terms that are favorable to us, if at all.

Our ability to raise additional funds when needed and on acceptable terms will depend on financial, economic and market conditions and other factors, over which we may have no or limited control.

See, for example, “— Changes in global economic and financial markets may have a negative effect on our business.

” If we fail to raise sufficient funds and incur losses, our ability to fund our operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive pressures could be significantly limited.

If this happens, we may be forced to delay or terminate research or development programs or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through collaborative and licensing arrangements that may require us to relinquish commercial rights, sell certain assets of the company which will limit future opportunities, or grant licenses on terms that are not favorable to us.

Without sufficient funding or revenue, we may have to curtail, cease, or dispose of one or more of our operations, which would have a material adverse effect on our business, financial condition, and future prospects.

Changes in global economic and financial markets may have a negative effect on our business.

Our business is subject to a variety of market forces including, but not limited to, domestic and international economic, political and social conditions.

Many of these forces are beyond our control, including generally weak or uncertain economic conditions, negative or uncertain political climates, changes in government and election results in the United States and other jurisdictions in which we operate.

Any change in market conditions that negatively impacts our operations or the demand of our current or prospective customers could adversely affect our business operations.

For example, economic uncertainty and volatility, including as a result of high-interest rates and inflation, have had and may continue to have a material adverse effect on our business.

Changes in the global financial, pharmaceutical and biotech markets may make it difficult to accurately forecast operating results.

These changes have had, and may continue to have, a negative effect on our business, results of operations, financial condition and liquidity.

In the event of a downturn in global economic activity, current or potential business partners may go out of business, may be unable to fund purchases or determine to reduce purchases, all of which could lead to reduced demand for our products and increased payment delays or defaults.

We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn given certain fixed costs associated with our operations and difficulties if we over strained our resources.

The timing and nature of a sustained recovery in the credit and financial markets remain uncertain, and there can be no assurance that market conditions will significantly improve in the near future or that our results will not continue to be materially and adversely affected.

In addition, geopolitical risks, including those arising from political turmoil, trade tension or the imposition of trade tariffs and/or sanctions, terrorist activity and acts of civil or international hostility, are increasing.

For instance, the ongoing military conflict between Russia and Ukraine, as well as conflicts in the Middle East have had negative impacts on the global economy and is expected to have further global economic consequences.

Any such events and responses, including regulatory developments, may cause significant volatility and declines in the global markets, disproportionate impacts to certain industries or sectors, disruptions to commerce (including to economic activity, travel and supply chains), loss of life and property damage, and may materially and adversely affect the global economy or capital markets, as well as our business and results of operations.

Our ability to raise

additional funds when needed and on acceptable terms will depend on financial, economic and market conditions and other factors,

over which we may have no or limited control.

See, for example, “- Changes in global economic and financial markets may have

a negative effect on our business.

” If we fail to raise sufficient funds and incur losses, our ability to fund our

operations, take advantage of strategic opportunities, develop products or technologies, or otherwise respond to competitive

pressures could be significantly limited.

If this happens, we may be forced to delay or terminate research or development programs

or the commercialization of products resulting from our technologies, curtail or cease operations or obtain funds through

collaborative and licensing arrangements that may require us to relinquish commercial rights, sell certain assets of the company

which will limit future opportunities, or grant licenses on terms that are not favorable to us.

Without sufficient funding or

revenue, we may have to curtail, cease, or dispose of one or more of our operations, which would have a material adverse effect on

our business, financial condition, and future prospects.

in global economic and financial markets may have a negative effect on our business.

business is subject to a variety of market forces including, but not limited to, domestic and international economic, political and social

Many of these forces are beyond our control, including generally weak or uncertain economic conditions, negative or uncertain

political climates, changes in government and election results in jurisdictions in which we operate.

Any change in market conditions

that negatively impacts our operations or the demand of our current or prospective customers could adversely affect our business operations.

For example, economic uncertainty and volatility, including as a result of high-interest rates and inflation, have had and may continue

to have a material adverse effect on our business.

Changes in global financial, pharmaceutical, biotechnology,

and broader economic markets may make it difficult to accurately forecast our operating results and may adversely affect our business,

results of operations, or financial condition.

In addition, adverse market conditions may impair our ability to raise additional capital on acceptable terms, or at all, which could

limit our ability to fund operations, execute our business strategy, or meet our obligations.

Such conditions could also affect our ability

to repay existing or future indebtedness, including secured loans, which could result in defaults, the loss of assets pledged as collateral,

or other adverse consequences.

We are also limited in our ability to reduce costs to offset the results of a prolonged or severe economic downturn

given certain fixed costs associated with our operations and difficulties if we over strain our resources.

The timing and nature of a

sustained recovery in the credit and financial markets remain uncertain, and there can be no assurance that market conditions will significantly

improve in the near future or that our results will not continue to be materially and adversely affected.

addition, geopolitical risks, including those arising from political turmoil, trade tension or the imposition of trade tariffs and “reciprocal”

tariffs (including those relating to Canada, Mexico, and China) and/or sanctions, terrorist activity and acts of civil or international

hostility, are increasing.

For instance, the ongoing military conflict between Russia and Ukraine, as well as conflicts in the Middle

East have had negative impacts on the global economy and is expected to have further global economic consequences, and there could be

similar impacts from ongoing tensions in Latin America and in Arctic regions.

Any such events and responses, including regulatory developments,

or the perception of instability may cause significant volatility and declines in the global markets, disproportionate impacts to certain

industries or sectors, disruptions to commerce (including to economic activity, travel and supply chains), loss of life and property

damage, and may materially and adversely affect the global economy or capital markets, as well as our business and results of operations.

Should an economic slowdown occur in the U.S.

or globally, our business and results of operations may be materially adversely affected.

We face risks related to widespread outbreaks of contagious disease or other biological threats, any of which could significantly disrupt our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties, including business development activities and research and development projects conducted by third party contract research organizations parties.

Significant outbreaks of contagious diseases, and other adverse public health developments, have had and could have a material impact on our business operations, financial condition, and operating results.

Pandemics and other outbreaks of contagious disease have in the past and could in the future significantly impact the operation of our business.

For example, pandemics have in the past adversely affected our ability to carry on certain business development activities, including as a result of restrictions in business-related travel, delays or disruptions in our on-going research projects, and unavailability of the employees of the Company or third-party contract research organizations with whom we conduct business, due to illness or quarantines.

In addition, pandemics and other outbreaks of contagious disease have in the past and may in the future exacerbate other risks disclosed in this Annual Report.

See, for example, “- Changes in global economic and financial markets may have a negative effect on our business.

” Whether and to what extent future pandemics and other outbreaks of contagious diseases may impact our financial and operational performance will depend on developments that include the duration, spread and severity of the outbreak, the timetable for administering and efficacy of vaccines, the duration and geographic scope of related travel advisories and restrictions and the extent of the impact of the pandemic or outbreak on overall demand for our products, technologies and services, and other factors beyond our control, all of which are highly uncertain and cannot be predicted.

Our sales and operations are subject to the risks of doing business internationally.

Our sales and operations are subject to the risks of doing business internationally, as we have customers and partners located outside of the United States.

face risks related to widespread outbreaks of contagious disease or other biological threats, any of which could significantly disrupt

our operations and have a material adverse effect on our business, employees, directors, consultants, collaborators and other third parties,

including business development activities and research and development projects conducted by third party contract research organizations

outbreaks of contagious diseases, and other adverse public health developments, have had and could have a material impact on our business

operations, financial condition, and operating results.

Pandemics and other outbreaks of contagious disease have in the past and could

in the future significantly impact the operation of our business.

For example, pandemics have adversely affected our ability to carry

on certain business development activities, including as a result of restrictions in business-related travel, delays or disruptions in

our on-going research projects, and unavailability of the employees of the Company or third-party organizations with

whom we conduct business, due to illness or quarantines.

In addition, pandemics and other outbreaks of contagious disease have in the

past and may in the future exacerbate other risks disclosed in this Annual Report.

See, for example, “- Changes in global economic

and financial markets may have a negative effect on our business.

” Whether and to what extent future pandemics and other outbreaks

of contagious diseases may impact our financial and operational performance will depend on developments that include the duration, spread

and severity of the outbreak, the timetable for administering and efficacy of vaccines, the duration and geographic scope of related

travel advisories and restrictions and the extent of the impact of the pandemic or outbreak on overall demand for our products, technologies

and services, and other factors beyond our control, all of which are highly uncertain and cannot be predicted.

sales and operations are subject to the risks of doing business internationally.

sales and operations are subject to the risks of doing business internationally, as we have customers and partners located outside of

the United States.

Conducting business internationally exposes us to a variety of risks, including:

Changes in or interpretations of foreign regulations that may adversely affect our ability to sell our products, repatriate profits to the United States or operate our foreign-located facilities;

Changes in or interpretations

of foreign regulations that may adversely affect our ability to sell our products, repatriate profits to the United States or operate

our foreign-located facilities;

The imposition of tariffs;

The imposition of limitations on, or increase of, withholding and other taxes on remittances and other payments by our foreign subsidiary or joint ventures;

Uncertainties relating to foreign laws, regulations and legal proceedings including tax, import/export, anti-corruption and exchange control laws;

The availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us;

Increased demands on our limited resources created by our operations may constrain the capabilities of our administrative and operational resources and restrict our ability to attract, train, manage and retain qualified management, technicians, scientists and other personnel;

Economic or political instability in foreign countries;

Difficulties associated with staffing and managing foreign operations;

The need to comply with a variety of United States and foreign laws applicable to the conduct of international business, including import and export control laws and anti-corruption laws.

Any violations of international laws and regulations may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

If we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could delay our technology and product development programs and harm our R&D efforts, and we may be unable to pursue research funding, licenses and other forms of collaborations or develop our own products.

Our planned activities will require retention, and ongoing recruiting of additional expertise in specific areas applicable to our industries, technologies and products being developed.

These activities will not only require the development of additional expertise by existing management personnel, but also the addition of new research and scientific, regulatory, licensing, sales, marketing, management, accounting and finance and other personnel.

The inability to acquire or develop this expertise or the loss of principal members of our management, board of directors, consultants, accounting and finance, sales, and scientific staff could impair the growth, if any, of our business.

However, competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited number of individuals who possess the skills and experience required by our industry.

As such, competition for experienced personnel from numerous companies, academic institutions and other research facilities may limit our ability to attract and retain qualified management, directors, consultants, and scientific personnel on acceptable terms.

Failure to attract and retain qualified personnel would inhibit our ability to maintain and pursue collaborations and develop our products and core technologies.

Personnel changes may disrupt our operations.

Hiring and training new personnel will entail costs and may divert our resources and attention from revenue-generating efforts.

Immigration enforcement

or other limitations on cross-border travel;

The imposition of limitations

on, or increase of, withholding and other taxes on remittances and other payments by our foreign subsidiary or joint ventures;

Uncertainties relating

to foreign laws, regulations and legal proceedings including tax, import/export, anti-corruption and exchange control laws;

The availability of government

subsidies or other incentives that benefit competitors in their local markets that are not available to us;

Increased demand on our

limited resources created by our operations may constrain the capabilities of our administrative and operational resources and restrict

our ability to attract, train, manage and retain qualified management, technicians, scientists and other personnel;

Economic or political instability

in foreign countries;

Difficulties associated

with staffing and managing foreign operations (including foreign currency exchange rates);

The need to comply with

a variety of United States and foreign laws applicable to the conduct of international business, including import and export control

laws and anti-corruption laws.

violations of international laws and regulations may result in substantial civil and criminal fines and penalties, imprisonment, the

loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other

consequences.

we lose key personnel, including key management or board members, or are unable to attract and retain additional personnel, it could

delay our technology and product development programs and harm our R&D efforts, and we may be unable to pursue research funding,

licenses and other forms of collaborations or develop our own products.

planned activities will require retention, and ongoing recruitment of additional expertise in specific areas applicable to our industries,

technologies and products being developed.

These activities will not only require the development of additional expertise by existing

management personnel, but also the addition of new research and scientific, regulatory, licensing, sales, marketing, management, accounting

and finance and other personnel.

The inability to acquire or develop this expertise or the loss of principal members of our management,

board of directors, consultants, accounting and finance, sales, and scientific staff could impair the growth, if any, of our business.

However, competition for qualified personnel in the pharmaceutical, biopharmaceutical and biotechnology field is intense due to the limited

number of individuals who possess the skills and experience required by our industry.

As such, competition for experienced personnel

from numerous companies, academic institutions and other research facilities may limit our ability to attract and retain qualified management,

directors, consultants, and scientific personnel on acceptable terms.

Failure to attract and retain qualified personnel would inhibit

our ability to maintain and pursue collaborations and develop our products and core technologies.

We may also face challenges in connection

with designing and executing on succession plans regarding members of senior management, which are heightened by the highly specialized

nature of our business.

changes may disrupt our operations.

Hiring and training new personnel will entail costs and may divert our resources and attention from

revenue-generating efforts.

In addition, we periodically engage consultants to assist us in our business and operations.

These consultants operate as independent contractors, and we therefore do not have as much control over their activities as we do over the activities of our employees.

Our directors and consultants may be affiliated with or employed by other parties, and some may have consulting or other advisory arrangements with other entities that may conflict or compete with their obligations to us.

Our product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.

Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt product development and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities and potential product liability claims.

Many compounds developed in the biopharmaceutical industry that initially showed promise in early stages have later been found to cause side effects that prevented their further development.

Any of these occurrences may materially and adversely affect our business, financial condition, results of operations and prospects.

We may be sued for product liability.

We or our current and future collaborators and licenses may be held liable if any product we or they develop, or any product which is made with the use or incorporation of, any of our technologies, causes injury or is found otherwise unsuitable or unsafe during product testing, manufacturing, marketing or sale.

These claims could be brought by various parties, including other companies who purchase products from our current and future collaborators and licenses or by end users of the products.

If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates.

Even a successful defense would require significant financial and management resources.

Regardless of the merits or eventual outcome, liability claims may result in:

Decreased demand for our current or future product candidates;

These consultants

operate as independent contractors, and we therefore do not have as much control over their activities as we do over the activities of

our employees.

Our directors and consultants may be affiliated with or employed by other parties, and some may have consulting or other

advisory arrangements with other entities that may conflict or compete with their obligations to us.

product candidates may cause undesirable and unforeseen side effects or have other properties impacting safety that could halt their

clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative

consequences.

side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt product development

and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other regulatory authorities

and potential product liability claims.

Many compounds developed in the biopharmaceutical industry that initially showed promise in early

stages have later been found to cause side effects that prevented their further development.

Any of these occurrences may materially

and adversely affect our business, financial condition, results of operations and prospects.

may be sued for product liability.

or our current and future collaborators and licenses may be held liable if any product we or they develop, or any product which is made

with the use or incorporation of, any of our technologies, causes injury or is found otherwise unsuitable or unsafe during product testing,

manufacturing, marketing or sale.

These claims could be brought by various parties, including other companies who purchase products from

our current and future collaborators and licenses or by end users of the products.

If we cannot successfully defend ourselves against

product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates.

a successful defense would require significant financial and management resources.

Regardless of the merits or eventual outcome, liability

claims may result in:

Decreased demand for our

current or future product candidates;

Injury to our reputation;

Costs to defend the related litigation;

Diversion of management’s time and our resources;

Regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions;

Costs to defend the related

Diversion of management’s

time and our resources;

Regulatory investigations,

product recalls, withdrawals or labeling, marketing or promotional restrictions;

Loss of revenue;

The inability to commercialize our current or any future product candidates.

While we maintain product liability insurance, it may not fully cover all of our potential liabilities and our liability could in some cases exceed our total assets, which would have a material adverse effect on our business, results of operations, financial condition and cash flows, or cause us to go out of business.

Further, insurance coverage is expensive and may be difficult to obtain and may not be available to us or to our collaborators and licensees in the future on acceptable terms, or at all.

Inability to obtain sufficient insurance coverage at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products developed by us, or our collaborators and licensees.

Foreign currency fluctuations could adversely affect our results.

In the conduct of our business, in certain instances, we are required to receive payments or pay our obligations in currencies other than U.S.

Especially since a large portion of our research and development is done in Europe, our CROs and certain consultants request payments in Euros.

As a result, we are exposed to changes in currency exchange rates with respect to our business transactions denominated in non-US dollars.

Fluctuations in currency exchange rates have in the past and may in the future negatively affect our revenue, expenses and our financial position and results of operations as expressed in U.S.

Our ability to use our net operating loss carryforwards ( “ NOLs ” ) to offset future taxable income may be subject to certain limitations.

In general, under Section 382 of the Internal Revenue Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its NOLs, to offset future taxable income.

If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code.

Future changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the Internal Revenue Code.

The inability to commercialize

our current or any future product candidates.

we maintain product liability insurance, it may not fully cover all of our potential liabilities and our liability could in some cases

exceed our total assets, which would have a material adverse effect on our business, results of operations, financial condition and cash

flows, or cause us to go out of business.

Further, insurance coverage is expensive and may be difficult to obtain and may not be available

to us or to our collaborators and licensees in the future on acceptable terms, or at all.

Inability to obtain sufficient insurance coverage

at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products

developed by us, or our collaborators and licensees.

currency fluctuations could adversely affect our results.

the conduct of our business, in certain instances, we are required to receive payments or pay our obligations in currencies other than

Especially since a large portion of our research and development is performed through our CROs in Europe, and certain consultants request

payments in Euros.

As a result, we are exposed to changes in currency exchange rates with respect to our business transactions denominated

in non-US dollars.

Fluctuations in currency exchange rates have in the past and may in the future negatively affect our revenue, expenses

and our financial position and results of operations as expressed in U.S.

Our ability to use our net operating loss carryforwards

( “ NOLs ” ) to offset future taxable income may be subject to certain limitations.

In general, under Section 382 of the Internal Revenue

Code, a corporation that undergoes an “ownership change” is subject to limitations on its ability to utilize its NOLs, to

offset future taxable income.

If the Internal Revenue Service challenges our analysis that our existing NOLs are not subject to limitations

arising from previous ownership changes, our ability to utilize NOLs could be limited by Section 382 of the Internal Revenue Code.

changes in our stock ownership, some of which are outside of our control, could result in an ownership change under Section 382 of the

Internal Revenue Code.

Furthermore, our ability to utilize NOLs of companies that we may acquire in the future may be subject to limitations.

We may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.

We may seek to expand our business through the acquisition of, investment in and strategic alliances with companies, technologies, products, and services.

If we are able to identify suitable acquisition, investment or strategic alliance targets, we may be unable to successfully negotiate their acquisition at a price or on terms and conditions acceptable to us.

We cannot assure you that, following an acquisition, investment or strategic alliance, we will achieve expected research and development results, anticipated synergies, revenues, specific net income or loss levels that justify such transaction or that the transaction will result in increased earnings, or reduced losses, for the combined company in any future period.

Moreover, we may need to raise additional funds through public or private debt or equity financing to acquire any businesses or to provide funding for such business, which would result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable to us.

We may not be able to oversee such investments nor operate acquired businesses profitably or otherwise implement our growth strategy successfully.

We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.

In the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary business information and personal information.

Despite the implementation of security measures, our internal computer systems and those of third parties with which we contract are vulnerable to damage from cybersecurity attacks, ransomware attacks, breaches, intentional or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, malware, exploit of unpatched product or service vulnerabilities, unauthorized access attempts (including third parties gaining access to systems using stolen or inferred credentials), denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism, war and telecommunication and electrical failures.

As the cyber-threat landscape evolves, these attacks are growing in frequency, levels of persistence, sophistication and intensity, are becoming increasingly difficult to detect, and are being conducted by sophisticated groups and individuals with a wide range of motives and expertise.

Furthermore, because the techniques used to obtain unauthorized access to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate these techniques or implement adequate preventative measures.

We may also experience security breaches that may remain undetected for an extended period.

Resulting system failures, accidents, or security breaches could cause interruptions in our operations and could result in a material disruption of our research activities and business operations, in addition to possibly requiring substantial expenditures of resources to remedy.

While we have experienced and continue to experience system failures, accidents and security breaches from time to time, none has been material to date.

To the extent that any disruption or security breach was to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and delays in our research efforts and financial reporting compliance, as well as a significant increase in costs to recover or reproduce the data.

Of special note is our risk when implementing new capabilities.

The implementation of new systems and information technology could adversely impact our operations by requiring substantial capital expenditures, diverting management’s attention, or causing delays or difficulties in transitioning to new systems.

As we implement new systems, many times both new and old systems run in parallel until all processes have successfully transferred to the new system and thorough testing has been performed.

These events could impact our customers, suppliers, subcontractors, employees, our financial reporting and our reputation and lead to financial losses from remediation actions, loss of business or potential liability, or an increase in expense, all of which may have a material adverse effect on our business.

Our systems implementations may also not result in productivity improvements at the levels anticipated.

In addition, the rapid evolution and increased adoption of artificial intelligence technologies may intensify our cybersecurity risks.

See “— The use of new and evolving technologies, such as artificial intelligence ( “ AI ” ), in our business may result in reputational harm, competitive harm or legal liability.

” Likewise, cyber incidents, including malicious cyber-attacks perpetrated on our employees and cyber incidents caused by third parties surreptitiously accessing our systems by other means, are an on-going risk to the security of the systems, networks, inf ormation and data of ours, our customers, subcontractors and suppliers.

While we have security, internal control and technology measures in place to protect our systems and networks, confidential business information, personal data of ours, our customers, employees, suppliers and subcontractors, our information technology systems and those of our third-party service providers have been and may in the future be subject to system breaches.

System breaches can lead to disclosure, modification and destruction of proprietary business data, personally identifiable information, other sensitive information, production downtime or loss of business, and damage to our reputation, competitiveness and operations.

In addition, flexible working arrangements and remote working for overseas consultants may adversely impact our ability to maintain the security, proper function and availability of our information technology and systems since remote working by our employees and consultants could strain our technology resources and introduce operational risk, including heightened cybersecurity risk.

Remote working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that have sought, and may seek, to exploit remote working environments.

In addition, current and future laws and regulations governing data privacy and the unauthorized disclosure of confidential information, including, but not limited to rules implemented by the SEC in 2023, may pose complex compliance challenges and result in additional costs.

may make acquisitions, investments and strategic alliances that may use significant resources, result in disruptions to our business

or distractions of our management, may not proceed as planned, and could expose us to unforeseen liabilities.

may seek to expand our business through the acquisition of, or investment in, strategic alliances with companies, technologies,

products, and services.

If we are able to identify suitable acquisition, investment or strategic alliance targets, we may be unable

to successfully negotiate their acquisition at a price or on terms and conditions acceptable to us.

cannot assure you that, following an acquisition, investment or strategic alliance, we will achieve expected research and development

results, anticipated synergies, revenues, specific net income or loss levels that justify such transaction or that the transaction will

result in increased earnings, or reduced losses, for the combined company in any future period.

Moreover, we may need to raise additional

funds through public or private debt or equity financing to acquire any businesses or to provide funding for such business, which would

result in dilution for stockholders or the incurrence of indebtedness and may not be available on terms which would otherwise be acceptable

We may not be able to oversee such investments nor operate acquired businesses profitably or otherwise implement our growth strategy

successfully.

rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including

any cybersecurity incidents, could harm our ability to operate our business effectively.

the ordinary course of our business, we collect, store and transmit confidential information, including intellectual property, proprietary

business information and personal information.

Despite the implementation of security measures, our internal computer systems and those

of third parties with which we contract are vulnerable to damage from cybersecurity attacks, ransomware attacks, breaches, intentional

or accidental mistakes or errors, or other technological failures, which can include, among other things, computer viruses, malware,

exploit of unpatched product or service vulnerabilities, unauthorized access attempts (including third parties gaining access to systems

using stolen or inferred credentials), denial-of-service attacks, phishing attempts, service disruptions, natural disasters, fire, terrorism,

war and telecommunication and electrical failures.

As the cyber-threat landscape evolves, these attacks are growing in frequency, levels

of persistence, sophistication and intensity, are becoming increasingly difficult to detect, and are being conducted by sophisticated

groups and individuals with a wide range of motives and expertise.

Furthermore, because the techniques used to obtain unauthorized access

to, or to sabotage, systems change frequently and often are not recognized until launched against a target, we may be unable to anticipate

these techniques or implement adequate preventative measures.

We may also experience security breaches that may remain undetected for

an extended period.

Resulting system failures, accidents, or security breaches could cause interruptions in our operations and could

result in a material disruption of our research activities and business operations, in addition to possibly requiring substantial expenditures

of resources to remedy.

To the extent that any disruption or security breach was to result

in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could

incur liability and delays in our research efforts and financial reporting compliance, as well as a significant increase in costs to recover

or reproduce the data.

special note is our risk when implementing new capabilities.

The implementation of new systems and information technology could adversely

impact our operations by requiring substantial capital expenditures, diverting management’s attention, or causing delays or difficulties

in transitioning to new systems.

As we implement new systems, many times both new and old systems run in parallel until all processes

have successfully transferred to the new system and thorough testing has been performed.

These events could impact our customers, suppliers,

subcontractors, employees, our financial reporting and our reputation and lead to financial losses from remediation actions, loss of

business or potential liability, or an increase in expenses, all of which may have a material adverse effect on our business.

implementations may also not result in productivity improvements at the levels anticipated.

In addition, the rapid evolution and increased

adoption of artificial intelligence technologies may intensify our cybersecurity risks.

See “- The use of new and evolving technologies,

such as artificial intelligence ( “ AI ” ), in our business may result in reputational harm, competitive harm or

legal liability.

” Likewise, cyber incidents, including malicious cyber-attacks perpetrated on our employees and cyber incidents

caused by third parties surreptitiously accessing our systems by other means, are an on-going risk to the security of the systems, networks,

information and data of ours, our customers, subcontractors and suppliers.

While we have security, internal control and technology measures

in place to protect our systems and networks, confidential business information, personal data of ours, our customers, employees, suppliers

and subcontractors, our information technology systems and those of our third-party service providers have been and may in the future

be subject to system breaches.

System breaches can lead to disclosure, modification and destruction of proprietary business data, personally

identifiable information, other sensitive information, production downtime or loss of business, and damage to our reputation, competitiveness

and operations.

In addition, flexible working arrangements and remote working for overseas consultants may adversely impact our ability

to maintain the security, proper function and availability of our information technology and systems since remote working by our employees

and consultants could strain our technology resources and introduce operational risk, including heightened cybersecurity risk.

working environments may be less secure and more susceptible to hacking attacks, including phishing and social engineering attempts that

have sought, and may seek, to exploit remote working environments.

In addition, current and future laws and regulations governing data

privacy and the unauthorized disclosure of confidential information may pose complex compliance challenges and result in additional costs.

A failure to comply with such laws and regulations could result in penalties or fines, legal liabilities or reputational harm.

The continuing and evolving threat of cyber-attacks has also resulted in increased regulatory focus on risk management and prevention.

New cyber-related regulations or other requirements could require significant additional resources and cause us to incur significant costs, which could have an adverse effect on our results of operations and cash flows.

The use of new and evolving technologies, such as artificial intelligence ( “ AI ” ), in our business may result in reputational harm, competitive harm or legal liability.

We have in the past and will in the future integrate new and evolving technologies, such as AI, into our business.

As with many innovations, AI presents risks and challenges that could affect its adoption and, as a result, our business.

Our implementation of AI in our business may have unintended consequences due to its inherent limitations or our failure to use it effectively.

For example, AI algorithms may be flawed due to a lack of back-testing or datasets of poor quality or inappropriate bias, and analyses generated by AI may be deficient or inaccurate, subjecting us to competitive or reputational harm.

The continuing

and evolving threat of cyber-attacks has also resulted in increased regulatory focus on risk management and prevention.

New cyber-related

regulations or other requirements could require significant additional resources and cause us to incur significant costs, which could

have an adverse effect on our results of operations and cash flows.

use of new and evolving technologies, such as artificial intelligence ( “ AI ” ), in our business

may result in reputational harm, competitive harm or legal liability.

have in the past and will in the future integrate new and evolving technologies, such as AI, into our business.

As with many innovations,

AI presents risks and challenges that could affect its adoption and, as a result, our business.

Our implementation of AI in our business

may have unintended consequences due to its inherent limitations or our failure to use it effectively.

For example, AI algorithms may

be flawed due to a lack of back-testing or datasets of poor quality or inappropriate bias, and analyses generated by AI may be deficient,

offensive, or inaccurate, subjecting us to competitive or reputational harm.

Additionally, AI entails significant legal risks.

The intellectual property ownership and license rights of new technologies such as AI have not been fully addressed by U.S.

courts, and the use or adoption of such technologies in our business may expose us to potential intellectual property claims, breach of a data or software license, website terms of service claims, claimed violations of privacy rights or other tort claims.

Governmental regulation and laws related to AI may also increase the burden and cost of research and development or require increased transparency that makes it more difficult to protect our intellectual property.

Other jurisdictions may decide to adopt similar or more restrictive legislation rendering the use of such technologies challenging.

Social and ethical issues relating to the use of new and evolving technologies such as AI in our business could also harm our comp etitive position and brand, or create legal liability, and may cause us to incur additional research and development costs to resolve such issues.

The regulatory

landscape surrounding artificial intelligence is also evolving, and expanded use of machine learning technologies may become subject

to regulation under new laws or new applications of existing laws.

The intellectual property ownership and license rights of new technologies

such as AI have not been fully addressed by U.S.

or global courts, and the use or adoption of such technologies in our business may expose

us to potential intellectual property claims, breach of a data or software license, website terms of service claims, claimed violations

of privacy rights, consumer protection, anti-discrimination, employment, tort claims or other laws.

Governmental regulation and laws

related to AI may also increase the burden and cost of research and development or require increased transparency that makes it more

difficult to protect our intellectual property and maintain compliance.

Other jurisdictions may decide to adopt similar or more restrictive

legislation rendering the use of such technologies challenging.

Failure to comply with applicable AI-related regulations, or to adapt

to new regulatory requirements as they emerge, could result in fines, penalties, litigation, or restrictions on our business operations.

Social and ethical issues relating to the use of new and evolving technologies such as AI in our business could also harm our competitive

position and brand, or create legal liability, and may cause us to incur additional research and development costs to resolve such issues.

Lastly, the rapid evolution and increased adoption of AI technologies may intensify our cybersecurity risks.

For more information, see “— We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology, including any cybersecurity incidents, could harm our ability to operate our business effectively.

Changes to our outsourced software or infrastructure vendors as well as any sudden loss, breach of security, disruption or unexpected data or vendor loss associated with our information technology systems could have a material adverse effect on our business.

We rely on third-party software and infrastructure to run critical accounting, project management and financial information systems.

If software or infrastructure vendors decide to discontinue further development, integration or long-term maintenance support for our information systems, or there is any system interruption, delay, breach of security, loss of data or loss of a vendor, we may need to migrate some or all of our accounting, project management and financial information to other systems.

These disruptions could increase our operational expense as well as impact the management of our business operations, which could have a material adverse effect on our financial position, results of operations, cash flows and liquidity.

Risks Related to Dependence on Third Parties

We are dependent on collaborations with third parties, and if we fail to maintain or successfully manage existing, or enter into new, strategic collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability.

Our R&D revenue is generated from a small number of research collaborations.

These collaborations could be delayed or be discontinued, as they have in the past, at any time with little advance notice.

If these research collaborations are lost or do not perform as expected, it could have a material adverse effect on our business, financial condition and operating results.

Our ability to enter into, maintain and manage collaborations in our target markets is fundamental to the success of our business.

We currently rely on, and expect to continue to rely on, our current and future partners, in part, for research and development, manufacturing and distribution, sales and marketing services, and application and regulatory know how.

In addition, we intend to enter into additional collaborations to conduct research, develop, produce, market, license and sell our technologies and products and processes we anticipate developing.

For more information, see

“- We rely significantly on information technology and any failure, inadequacy, interruption or security lapse of that technology,

including any cybersecurity incidents, could harm our ability to operate our business effectively.

to our outsourced software or infrastructure vendors as well as any sudden loss, breach of security, disruption or unexpected data or

vendor loss associated with our information technology systems could have a material adverse effect on our business.

rely on third-party software and infrastructure to run critical accounting, project management and financial information systems.

software or infrastructure vendors decide to discontinue further development, integration or long-term maintenance support for our information

systems, or there is any system interruption, delay, breach of security, loss of data or loss of a vendor, we may need to migrate some

or all of our accounting, project management and financial information to other systems.

These disruptions could increase our operational

expense as well as impact the management of our business operations, which could have a material adverse effect on our financial position,

results of operations, cash flows and liquidity.

Related to Dependence on Third Parties

are dependent on collaborations with third parties, and if we fail to maintain or successfully manage existing, or enter into new, strategic

collaborations, we may not be able to develop and commercialize many of our technologies and products and achieve profitability.

R&D revenue is generated from a small number of research collaborations.

These collaborations could be delayed or discontinued, as

they have in the past, at any time with little advance notice.

If these research collaborations are lost or do not perform as expected,

it could have a material adverse effect on our business, financial condition and operating results.

ability to enter into, maintain and manage collaborations in our target markets is fundamental to the success of our business.

rely on, and expect to continue to rely on, our current and future partners, in part, for research and development, manufacturing and

distribution, sales and marketing services, and application and regulatory know how.

In addition, we intend to enter into additional

collaborations to conduct research, develop, produce, market, license and sell our technologies and products and processes we anticipate

However, we may not be successful in entering into collaborative arrangements with third parties.

Any failure to enter into such arrangements on favorable terms could delay or hinder our ability to develop and commercialize our technologies, products and processes and could increase our costs of research and development and commercialization.

We have limited or no control over the resources that any collaborator or licensee may devote to our programs, and reductions in collaborators ’ R&D budgets may affect our businesses.

Any of our current or future collaborators or licensees may breach or terminate their agreements with us or otherwise fail to perform and conduct their required activities successfully and in a timely manner.

Our collaborators or licensees may elect not to develop products arising out of our collaborative or license arrangements or may choose not to devote sufficient resources to the development, manufacture, market or sale of these products.

If any of these events occur, we or our collaborators or licensees may not develop our technologies or commercialize our or their products.

Fluctuations in the R&D budgets of government agencies, our customers, licensees, collaborators and research partners could have a significant impact on the interest in and demand for our technology.

Our businesses could be seriously damaged by significant decreases in life sciences and/or pharmaceutical R&D expenditures by government agencies and existing and potential partners.

We heavily rely on contracts with third-party CROs and other third-party service providers to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.

We are dependent upon the performance and research capacity of a number of third-party CROs and other service providers to conduct our research and development projects, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which include services and programs in connection with the modification and enhancement of the Company’s C1 platform and to support our business development efforts for C1’s use in biopharmaceutical and other applications.

For the year ended December 31, 2024, two CROs accounted for approximately 93.0% total research services we purchased and 58.9% of accounts payable.

For more information, see “Item 1.

Business—Our Research Partners and CROs.” The licensing and service arrangements with these third parties are not guaranteed to be obtained, renewed or continued on reasonable terms, if at all.

The Company may be unable to obtain, maintain or expand its access to third party CROs and other service providers to conduct these services.

Failure to obtain, maintain and expand access to certain third party CROs and other service providers could have a material adverse impact on the Company’s research projects, financial condition and operating results.

In addition, from time to time there are disagreements with such third parties that if not resolved can have a material adverse effect on our business, financial condition and operating results.

In sum, the loss of business from one of these CROs or a combination of them could in certain cases make it difficult to find a replacement and in turn adversely affect our operations.

We are also heavily dependent upon the availability and performance of third-party research organizations.

If we require research capacity and/or capabilities and are unable to obtain it in sufficient quantity, and quality or at terms and conditions that are acceptable to the Company or our third party collaborators, we may not be able to offer our technologies or products for license, or sale, or we may be required to make substantial capital investments to build out that capacity or to contract with other research organizations on terms that may be less favorable than our current arrangements.

In addition, if we contract with other research organizations, we may experience delays of several months in qualifying them or in starting up research programs at these facilities, which could harm our relationships with our licensees, collaborators or customers, and we may be required to make a capital investment in connection with these arrangements.

Any failure to enter into

such arrangements on favorable terms could delay or hinder our ability to develop and commercialize our technologies, products and processes

and could increase our costs of research and development and commercialization.

have limited or no control over the resources that any collaborator or licensee may devote to our programs, and reductions in collaborators ’

R&D budgets may affect our businesses.

of our current or future collaborators or licensees may breach or terminate their agreements with us or otherwise fail to perform and

conduct their required activities successfully and in a timely manner.

Our collaborators or licensees may elect not to develop products

arising out of our collaborative or license arrangements or may choose not to devote sufficient resources to the development, manufacture,

market or sale of these products.

If any of these events occur, we or our collaborators or licensees may not develop our technologies

or commercialize our or their products.

in the R&D budgets of government agencies, our customers, licensees, collaborators and research partners could have a significant

impact on the interest in and demand for our technology.

Our businesses could be seriously damaged by significant decreases in life sciences

and/or pharmaceutical R&D expenditures by government agencies and existing and potential partners.

heavily rely on contracts with third-party CROs and other third-party service providers across all aspects of our business,

including to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical

trials, which may not be available to the Company on commercially reasonable terms or at all.

are dependent upon the performance and research capacity of a number of third-party CROs and other service providers to conduct our

research and development projects, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which

include services and programs in connection with the modification and enhancement of the Company’s C1 platform and to support

our business development efforts for C1’s use in biopharmaceutical and other applications.

For the year ended December 31,

2025, two CROs accounted for approximately 90.9% of total research services we purchased and 67.0% of accounts payable.

information, see “Item 1.

Business-Our Research Partners and CROs.” The licensing and service arrangements with these

third parties are not guaranteed to be obtained, renewed or continued on reasonable terms, if at all.

The Company may be unable to

obtain, maintain or expand its access to third party CROs and other service providers to conduct these services.

Failure to obtain,

maintain and expand access to certain third party CROs and other service providers could have a material adverse impact on the

Company’s research projects, financial condition and operating results.

In addition, from time to time there are disagreements

with such third parties that if not resolved can have a material adverse effect on our business, financial condition and operating

In conclusion, the loss of business from one of these CROs or a combination of them could in certain cases make it

difficult to find a replacement and in turn adversely affect our operations.

are also heavily dependent upon the availability and performance of third-party research organizations.

If we require research capacity

and/or capabilities and are unable to obtain it in sufficient quantity, and quality or at terms and conditions that are acceptable to

the Company or our third party collaborators, we may not be able to offer our technologies or products for license, or sale, or we may

be required to make substantial capital investments to build out that capacity or to contract with other research organizations on terms

that may be less favorable than our current arrangements.

In addition, if we contract with other research organizations, we may experience

delays of several months in qualifying them or in starting up research programs at these facilities, which could harm our relationships

with our licensees, collaborators or customers, and we may be required to make a capital investment in connection with these arrangements.

This could have a material adverse effect on our business, revenues or operating results.

Additionally, if we were to be unsuccessful in retaining a CRO with the requisite experience and skills we require and were required to build our own research facility, it could take a year or longer before such owned research facility were able to be brought online to carry out the necessary technology and product development efforts of the Company.

Conflicts with the CROs, other service providers, collaborators and/or licensees could harm our business.

An important part of our strategy includes involvement in proprietary research programs.

We may pursue opportunities in the pharmaceutical and other fields that could conflict with those of our collaborators and licensees.

Moreover, disagreements with Danisco, our current and/or future CROs, other service providers, collaborators or licensees could develop over rights to our intellectual property, over further licensing of our technologies to other parties in certain pharmaceutical and other fields, or for other reasons.

Any conflict with Danisco, our current and/or future CROs, other service providers, collaborators or licensees could reduce our ability to obtain future collaboration agreements and negatively impact our relationship with existing collaborators or licensees, which could reduce our revenues and profits.

For more information, see “Risk Factors— We heavily rely on contracts with third-party CROs and other third-party service providers to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical trials, which may not be available to the Company on commercially reasonable terms or at all.

Some of our current and/or future CROs, other service providers, collaborators and/or licensees could also become competitors in the future.

Our current and/or future CROs, other service providers, collaborators and/or licensees could develop competing technologies or products, preclude us from entering into collaborations or license agreements with their customers, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of their technology and products and processes.

Any of these developments could harm our technology development and value, product development efforts, revenue, profits and overall business.

We rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial results as required by law.

We need to receive timely, accurate and complete information from a number of third parties in order to accurately and timely report our financial results.

We rely on third parties to provide us with complete and accurate information regarding research developments and data, revenues, expenses and payments owed to or by us on a timely basis.

We rely on the proper controls and procedures related to obtaining and reporting information from our CROs, licensees and collaborators related to research results and other data, when milestones are earned, if any, when royalties are earned, if any, as well as other types of potential revenues and expenses.

If the information that we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement.

As a result, we may have difficulty in completing accurate and timely financial disclosures, which could have a material adverse effect on our business, financial condition and results of operations and the market price of our common stock.

Risks Related to Government Regulations and Environmental, Social, and Governance Issues

Potential future regulations limiting our ability to sell genetically engineered products could harm our business.

We, our current and future collaborators and licensees expect to develop biologic products using genetically engineered microorganisms (“GMOs”).

Products derived from GMOs may in some instances be subject to bans or additional or changing regulation by federal, state, local and foreign government agencies.

These agencies may not allow us or our collaborators and licensees to produce and market products derived from GMOs in a timely manner or under technically or commercially feasible conditions.

Compliance with FDA, Environmental Protection Agency (“EPA”) and EU regulations could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products.

The FDA currently applies the same regulatory standards to products made through genetic engineering as those applied to products developed through traditional methodologies.

Regardless of GMO status, a product may be subject to lengthy FDA reviews and unfavorable FDA determinations due to safety concerns or changes in the FDA’s regulatory policy.

Additionally,

arrangements with these third parties and service providers may not be available or we may be unsuccessful in retaining a third

party with the requisite experience and skills we require and were required to build our own research facility, it could take a year

or longer before such owned research facility were able to be brought online to carry out the necessary technology and product

development efforts of the Company.

The loss of, or disruption in services from, one of our third parties could make it difficult to replace such a third

party on a timely or cost-effective basis.

If we are unable to secure these third parties, or if such services are available on commercially

impracticable terms, we may experience delays in development, regulatory processes, and commercialization, all of which would adversely

affect our business operations and financial condition.

with the CROs, other service providers, collaborators and/or licensees could harm our business.

important part of our strategy includes involvement in proprietary research programs.

We may pursue opportunities in the pharmaceutical

and other fields that could conflict with those of our collaborators and licensees.

Moreover, disagreements with Danisco, our current

and/or future CROs, other service providers, collaborators or licensees could develop over rights to our intellectual property, over

further licensing of our technologies to other parties in certain pharmaceutical and other fields, or for other reasons.

with Danisco, our current and/or future CROs, other service providers, collaborators or licensees could reduce our ability to obtain

future collaboration agreements and negatively impact our relationship with existing collaborators or licensees, which could reduce our

revenues and profits.

For more information, see “Risk Factors- We heavily rely on contracts with third-party CROs and other third-party

service providers to conduct our research and development, pre-clinical, CMC and cGMP manufacturing, fill and finish, and potential clinical

trials, which may not be available to the Company on commercially reasonable terms or at all.

of our current and/or future CROs, other service providers, collaborators and/or licensees could also become competitors in the future.

Our current and/or future CROs, other service providers, collaborators and/or licensees could develop competing technologies or products,

preclude us from entering into collaborations or license agreements with their customers, fail to obtain timely regulatory approvals,

terminate their agreements with us prematurely or fail to devote sufficient resources to the development and commercialization of their

technology and products and processes.

Any of these developments could harm our technology development and value, product development

efforts, revenue, profits and overall business.

rely on our collaborators and other third parties to deliver timely and accurate information in order to accurately report our financial

results as required by law.

need to receive timely, accurate and complete information from a number of third parties in order to accurately and timely report our

financial results.

We rely on third parties to provide us with complete and accurate information regarding research developments and

data, revenues, expenses and payments owed to or by us on a timely basis.

We rely on the proper controls and procedures related to obtaining

and reporting information from our CROs, licensees and collaborators related to research results and other data, when milestones are

earned, if any, when royalties are earned, if any, as well as other types of potential revenues and expenses.

If the information that

we receive is not accurate, our consolidated financial statements may be materially incorrect and may require restatement.

we may have difficulty in completing accurate and timely financial disclosures, which could have a material adverse effect on our business,

financial condition and results of operations and the market price of our common stock.

Related to Government Regulations and Sustainability Issues

future regulations limiting our ability to sell genetically engineered products could harm our business.

our current and future collaborators and licensees expect to develop biologic products using genetically engineered microorganisms (“GMOs”).

Products derived from GMOs may in some instances be subject to bans or additional or changing regulation by federal, state, local and

foreign government agencies.

These agencies may not allow us or our collaborators and licensees to produce and market products derived

from GMOs in a timely manner or under technically or commercially feasible conditions.

with FDA, Environmental Protection Agency (“EPA”) and EU regulations could result in expenses, delays or other impediments

to our product development programs or the commercialization of resulting products.

The FDA currently applies the same regulatory standards

to products made through genetic engineering as those applied to products developed through traditional methodologies.

Regardless of

GMO status, a product may be subject to lengthy FDA reviews and unfavorable FDA determinations due to safety concerns or changes in the

FDA’s regulatory policy.

The EPA regulates biologically derived enzyme-related chemical substances not within the FDA’s jurisdiction.

An unfavorable EPA ruling could delay commercialization or require modification of the production process or product in question, resulting in higher manufacturing costs, thereby making the product uneconomical.

The EU and other countries also have regulations regarding the development, production and marketing of products from GMOs, which may be as or more restrictive than U.S.

Further, we, Danisco, and our current and future collaborators and licensees are subject to regulations in the other countries in which we operate outside of the U.S.

An unfavorable EPA ruling could delay commercialization or require modification of the production process or product in question, resulting

in higher manufacturing costs, thereby making the product uneconomical.

The EU and other countries also have regulations regarding the

development, production and marketing of products from GMOs, which may be as or more restrictive than U.S.

we, Danisco, and our current and future collaborators and licensees are subject to regulations in the other countries in which we operate

outside of the U.S.

and EU, which may have different rules and regulations depending on the jurisdiction.

Different countries have different rules regarding which products qualify as GMOs.

If any of these countries expand the definition of GMO and increase the regulatory burden on GMO products, our business could be harmed.

Other changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies, may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our business or financial results.

Our employees and independent contractors, including principal investigators, CROs, consultants and vendors, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.

We are exposed to the risk that our employees and independent contractors, including principal investigators, CROs, consultants and vendors may violate (intentionally or unintentionally) our internal processes and procedures, or engage in misconduct or other illegal activity.

Such actions could include intentional, reckless and/or negligent conduct or disclosure of unauthorized activities to us that violate:

(1) the laws and regulations of the FDA and other similar regulatory requirements, including those laws that require the reporting of true, complete and accurate information to such authorities, (2) manufacturing standards, including cGMP requirements, (3) data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad or (4) laws that require the true, complete and accurate reporting of financial information or data.

Activities subject to these laws also involve the improper use or misrepresentation of information obtained in the course of clinical trials, the creation of fraudulent data in our preclinical studies or clinical trials, or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation.

It is not always possible to identify, prevent and deter these activities and/or misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations.

In addition, we are subject to the risk that a person or government could allege such actions, including fraud or other misconduct, even if none occurred.

If any such actions are instituted against us, we may incur significant costs to respond, and if we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and financial results, including, without limitation, the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.

Public views on ethical and social issues may limit use of our technologies.

Our success will depend in part upon our ability, and our current and future collaborators’ or licensees’ ability, to develop pharmaceutical and non-pharmaceutical products discovered, developed and manufactured through the C1 platform, and our other technologies.

Governmental authorities could, for social, ethical or other purposes, limit the use of genetic processes or prohibit the practice of using a modified C1 organism to produce biologic vaccines, drugs and other biologic products.

Concerns about the C1 platform and our other technologies, and particularly about the expression of genes from C1 for pharmaceutical and non-pharmaceutical purposes, could adversely affect their market acceptance.

The commercial success of our current and future collaborations and our licensees’ potential products will depend in part on public acceptance of the use of genetically engineered products including enzymes, vaccines, drugs and other protein products produced in this manner.

Claims that genetically engineered products are unsafe for consumption or pose a danger to the environment, animals or humans may influence public attitudes.

Different countries have different

rules regarding which products qualify as GMOs.

If any of these countries expand the definition of GMO and increase the regulatory burden

on GMO products, our business could be harmed.

changes in regulatory requirements, laws and policies, or evolving interpretations of existing regulatory requirements, laws and policies,

may result in increased compliance costs, delays, capital expenditures and other financial obligations that could adversely affect our

business or financial results.

Our employees and independent contractors,

including principal investigators, CROs, CDMOs, consultants, vendors, and other service providers, may engage in misconduct or other

improper activities, including noncompliance with applicable laws, regulations, and our internal policies and procedures.

We are exposed to the risk that our employees

and independent contractors, including principal investigators, CROs, CDMOs, consultants, vendors, and other service providers may intentionally

or unintentionally violate our processes, engage in misconduct, or fail to comply with applicable regulatory requirements.

could violate the laws and regulations of the FDA or comparable foreign authorities, manufacturing requirements, including cGMP, data

privacy and security laws, healthcare-related laws, or laws requiring accurate financial reporting.

These risks also extend to activities

related to GRAS determinations or similar filings and studies or trials .

addition, misconduct could involve the improper use, misrepresentation, or fabrication of data, unauthorized disclosure of confidential

information, or misappropriation of materials or products.

Any such actions could result in regulatory enforcement actions, delays in

development or commercialization, or significant reputational harm.

It is not always possible to identify, prevent, or deter such misconduct,

and the controls and procedures we have implemented may not be effective in mitigating all risks or losses or in protecting us from governmental

investigations, enforcement actions, or litigation.

We may also be subject to allegations of misconduct or noncompliance, including claims of fraud or regulatory violations.

Defending against

such claims can be costly and time-consuming and may divert management’s attention and resources.

If we or our collaborators or

licensees are found to be in violation of applicable laws or regulations, our business operations and financial condition may be adversely

views on ethical and social issues may limit use of our technologies.

success will depend in part upon our ability, and our current and future collaborators’ or licensees’ ability, to develop

pharmaceutical and non-pharmaceutical products discovered, developed and manufactured through the C1 platform, and our other technologies.

Governmental authorities could, for social, ethical or other purposes, limit the use of genetic processes or prohibit the practice of

using a modified C1 organism to produce biologic non-therapeutic products.

Concerns about the C1 platform and our other technologies,

and particularly about the expression of genes from C1 for pharmaceutical and non-pharmaceutical purposes, could adversely affect their

market acceptance.

commercial success of our current and future collaborations and our licensees’ potential products will depend in part on public

acceptance of the use of genetically engineered products including enzymes, non-therapeutics, and other products produced in this manner.

Claims that genetically engineered products are unsafe for consumption or pose a danger to the environment, animals or humans may influence

public attitudes.

Our and our licensees’ genetically engineered products may not gain public acceptance.

Negative public reaction to GMOs and products could result in increased government regulation of genetic research and resulting products, including stricter labeling laws or other regulations, and could cause a decrease in the demand for our products.

If we and/or our collaborators are not able to overcome the ethical, legal, and social concerns relating to genetic engineering, some or all of our products and processes may not gain public acceptance, which could have a material adverse effect on our business, financial condition and results of operations.

Our results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.

We and the CROs, collaborators and licensees are subject to various federal, state and local environmental laws and regulations relating to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of hazardous materials, and the health and safety of our employees.

These laws, regulations and permits can often require expensive pollution control equipment or operational changes to limit actual or potential impacts to the environment.

Even then, we cannot eliminate the risk of contamination or injury from these materials.

A violation of these laws and regulations or permit conditions could result in substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.

In recent years, environmental, health and safety laws and regulations have become increasingly more stringent, although this may change under the new U.S.

presidential administration.

In addition, new laws, new interpretations of existing laws, increased government enforcement of environmental laws, or other developments could require us or our CROs or other service providers to make additional significant expenditures.

Present and future environmental laws and regulations and interpretations thereof, more vigorous enforcement of policies and discovery of currently unknown conditions may impair our research, development or production efforts or require substantial expenditures that could have a material adverse effect on our results of operations and financial position.

Additionally, any such developments may have a negative impact on our contract manufacturers, which could harm our business.

Increasing scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our environmental, social and governance practices may impose additional costs on us or expose us to new or additional risks.

Companies are facing increasing scrutiny from customers, regulators, investors, and other stakeholders related to their environmental, social and governance practices.

Investor advocacy groups, investment funds and influential investors are also increasingly focused on these practices, especially as they relate to the environment, health and safety, supply chain management, diversity and human rights.

Failure to adapt to or comply with regulatory requirements or investor or stakeholder expectations and standards could negatively impact our reputation and the price of our common stock.

In addition, our customers may adopt policies that include social and environmental requirements or may seek to include such provisions in their contract terms and conditions.

These social and environmental responsibility provisions and initiatives are subject to change and vary from jurisdiction to jurisdiction, and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity and the global scope of our operations.

In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to modify our sourcing practices or make other operational choices which may require additional investments and increase our costs or result in inefficiencies.

Any of the factors mentioned above, or the perception that we or those with whom we conduct business have not responded appropriately to the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material adverse effect on our business, financial condition, results of operations cash flows and/or the price of our common stock.

We have no experience submitting applications to the FDA or similar regulatory authorities in the past and may not be able to obtain regulatory approval or may be subject to lengthy and/or unfavorable regulatory proceedings.

While we understand that many of our current and future collaborators or licensees may have a proven track record of experience submitting application to the FDA or other applicable regulatory authorities, we have no such experience in the past.

Neither we nor any collaborator or licensee has yet submitted any application with the FDA or any other regulatory authority for any product candidate generated through the use of the C1 platform as it relates to the development and manufacture of pharmaceutical and other products.

The FDA may not have substantial experience with technology similar to ours, which could result in delays or regulatory action against us.

In addition, the new U.S.

presidential administration has indicated it may institute significant changes to certain regulatory agencies, including the FDA, and it is difficult to predict the impact of these changes, if any.

We and our current and future collaborators and licensees may not be able to able to obtain regulatory approval for C1 expressed products, which would harm our business.

The C1 platform has been tested for use in the manufacturing of an enzyme in the production of wine, beer and fruit juices, and has generated promising safety and toxicity data for that enzyme.

The C1 platform could produce vaccines, antibodies, or therapeutic products and enzymes that have safety, toxicity, pathogenicity, immunogenicity and other issues associated with them.

The C1 platform and our other technologies may be subject to lengthy regulatory reviews and unfavorable regulatory determinations if they raise safety questions which cannot be satisfactorily answered or if results from studies do not meet regulatory requirements.

An unfavorable regulatory ruling could be difficult to resolve and could delay or possibly prevent a product from being commercialized, or even delay or prevent the use of the C1 platform or our other technologies to produce future products, which would have a material adverse effect on our growth and prospects.

Additionally, future products produced by us or our current and future collaborators or licensees using the C1 platform, or our other technologies may not be approved by the FDA or other regulatory agencies in the U.S.

Negative public reaction

to GMOs and products could result in increased government regulation of genetic research and resulting products, including stricter labeling

laws or other regulations, and could cause a decrease in the demand for our products.

If we and/or our collaborators are not able to

overcome the ethical, legal, and social concerns relating to genetic engineering, some or all of our products and processes may not gain

public acceptance, which could have a material adverse effect on our business, financial condition and results of operations.

results of operations may be adversely affected by environmental, health and safety laws, regulations and liabilities.

and the CROs, collaborators and licensees are subject to various federal, state and local environmental laws and regulations relating

to the discharge of materials into the air, water and ground, the generation, storage, handling, use, transportation and disposal of

hazardous materials, and the health and safety of our employees.

These laws, regulations and permits can often require expensive pollution

control equipment or operational changes to limit actual or potential impacts on the environment.

Even then, we cannot eliminate the

risk of contamination or injury from these materials.

A violation of these laws and regulations or permit conditions could result in

substantial fines, criminal sanctions, permit revocations and/or facility shutdowns.

recent years, environmental, health and safety laws and regulations have become more prevalent.

In addition, new laws, new interpretations

of existing laws, or other developments could require us or our CROs or other service providers to make additional significant expenditures.

Present and future environmental laws and regulations and interpretations thereof, more vigorous enforcement of policies and discovery

of currently unknown conditions may impair our research, development or production efforts or require substantial expenditures that could

have a material adverse effect on our results of operations and financial position.

Additionally, any such developments may have a negative

impact on our contract manufacturers, which could harm our business.

scrutiny and changing expectations from customers, regulators, investors, and other stakeholders with respect to our sustainability practices

may impose additional costs on us or expose us to new or additional risks.

are facing scrutiny from customers, regulators, investors, and other stakeholders related to their sustainability practices.

advocacy groups, investment funds and influential investors are also focused on these practices, especially as they relate to the environment,

health and safety, supply chain management, diversity and human rights.

Failure to adapt to or comply with regulatory requirements or

investor or stakeholder expectations and standards could negatively impact our reputation and the price of our common stock.

addition, our customers may adopt policies that include sustainability requirements or may seek to include such provisions in their contract

terms and conditions.

These sustainability provisions and initiatives are subject to change and vary from jurisdiction to jurisdiction,

and certain elements may be difficult and/or cost prohibitive for us to comply with given the inherent complexity and the global scope

of our operations.

In certain circumstances, in order to meet the requirements or standards of our customers, we may be obligated to

modify our sourcing practices or make other operational choices which may require additional investment and increase our costs or result

in inefficiencies.

of the factors mentioned above, or the perception that we or those with whom we conduct business have not responded appropriately to

the growing concern for such issues, regardless of whether we are legally required to do so, may damage our reputation and have a material

adverse effect on our business, financial condition, results of operations cash flows and/or the price of our common stock.

have no experience submitting applications to the FDA or similar regulatory authorities in the past and may not be able to obtain regulatory

approval or may be subject to lengthy and/or unfavorable regulatory proceedings.

we understand that many of our current and future collaborators or licensees may have a proven track record of experience submitting

application to the FDA or other applicable regulatory authorities, we have no such experience in the past.

Neither we nor any collaborator

or licensee has yet submitted any application with the FDA or any other regulatory authority for any product candidate generated through

the use of the C1 platform as it relates to the development and manufacture of pharmaceutical and other products.

The FDA may not have

substantial experience with technology similar to ours, which could result in delays or regulatory action against us.

We and our current

and future collaborators and licensees may not be able to able to obtain regulatory approval for C1 expressed products, which would harm

our business.

C1 platform has been tested for use in the manufacturing of an enzyme in the production of wine, beer and fruit juices, and has generated

promising safety and toxicity data for that enzyme.

The C1 platform could produce non-therapeutic products that have safety, toxicity,

pathogenicity, immunogenicity and other issues associated with them.

The C1 platform and our other technologies may be subject to lengthy

regulatory reviews and unfavorable regulatory determinations if they raise safety questions which cannot be satisfactorily answered or

if results from studies do not meet regulatory requirements.

An unfavorable regulatory ruling could be difficult to resolve and could

delay or possibly prevent a product from being commercialized or even delay or prevent the use of the C1 platform or our other technologies

to produce future products, which would have a material adverse effect on our growth and prospects.

Additionally, future products produced

by us or our current and future collaborators or licensees using the C1 platform, or our other technologies may not be approved by the

FDA or other regulatory agencies in the U.S.

or worldwide.

There is no assurance that safety, toxicity, pathogenicity, immunogenicity and other issues will not arise in current or future product development and manufacturing programs due to media, fermentation, inherent properties or genetic changes in the C1 and other strains and fermentation processes.

If these therapeutic protein products, antibodies or vaccines or other non-pharmaceutical products are not approved by regulators, we or our current and future customers or collaborators and licensees will not be able to commercialize them, and we may not receive research funding, upfront license fees, milestone and royalty payments, which are based upon the successful advancement of these products through the drug development and approval process.

Even after investing significant time and expense, any regulatory approval may also impose limitations on the uses for which we can market a product, and any marketed product and its manufacturer are subject to continual review.

Discovery of previously unknown problems with a product or manufacturer may result in new restrictions on the product, manufacturer and manufacturing facility, including withdrawal of the product from the market.

In certain countries, regulatory agencies also set or approve prices, which may result in low or unprofitable margins and would have a material adverse effect on our business, financial condition and results of operations.

Risks Relating to Intellectual Property

Failure to protect our intellectual property and the intellectual property of certain third parties could harm our competitive position.

Our success will depend in part on our ability to obtain patents and on our and Danisco’s (as part of the DuPont Transaction, patents were assigned to Danisco) and our current and future collaborators’ and licensees’ ability to maintain adequate protection of our and their intellectual property.

If we, Danisco, or our current and future collaborators and licensees do not adequately protect our intellectual property, competitors may be able to practice our technologies and erode our competitive advantage.

The laws of some foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered significant problems in protecting their proprietary rights in these foreign countries.

However, the patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and factual questions.

We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our, and in certain instances the C1 patents assigned to Danisco, and our current and future collaborators’ and licensees’ proprietary technologies, are covered by valid and enforceable patents or are effectively maintained as trade secrets.

We intend, from time to time, to apply for patents covering both our technologies and our products, while at other times, we only maintain such knowledge as trade secrets without applying for patents, as we deem appropriate.

However, existing and future patent applications may be challenged and are not guaranteed to result in the issuing of patents.

Even if a patent is obtained, it may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products.

Others, including Danisco and our current and future collaborators and licensees, may independently develop similar or alternative technologies or design around our, Danisco’s or our current and future collaborators’ and licensees’ patented technologies.

In addition, Danisco, our current and future collaborators, licensees, or other third parties may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages.

If any third party is able to gain intellectual property protections for technology similar to our own, they may be successful in blocking us and our licensees from using the C1 platform or our other technologies and/or commercializing products derived from them.

We cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the claims upheld in our and other companies’ patents.

Given that the degree of future protection for our proprietary rights is uncertain, we cannot ensure that we were the first to invent the inventions covered by our pending patent applications, or that we were the first to file patent applications for these inventions or the patents we have obtained.

In addition, Dyadic will continue to review its existing and potential patent positions and rights.

Based on our analysis if and when the commercial opportunities and patent enforceability are questionable, we may abandon certain patents in some countries.

There is a risk that we will abandon potentially valuable patents.

Litigation or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock price.

Our commercial success depends in part on neither infringing patents and proprietary rights of third parties, nor breaching any licenses that we have entered into with regard to our technologies and products.

Others have filed, and in the future are likely to file, patent applications covering genes or gene fragments, genetic elements, screening, gene expression and fermentation processes and other intellectual property that we may wish to utilize with the C1 platform or our other technologies or products and systems that are similar to those developed with its use.

If these patent applications result in issued patents and we wish to use the claimed technology, we may need to obtain a license from the appropriate third party.

Third parties do and may continue to assert that we and/or our current and future collaborators and licensees are employing their proprietary technology without authorization.

In addition, third parties may obtain patents in the future and claim that use of our technologies infringes these patents.

We could incur substantial costs and diversion of management and technical personnel in defending ourselves against any of these claims or enforcing our patents and other intellectual property rights.

Parties making claims against us may be able to obtain injunctive or other equitable relief, which could effectively block our ability to further develop, commercialize and sell products, and could result in the award of substantial damages against us.

If a claim of infringement against us is successful, we may be required to pay damages and obtain one or more licenses from third parties.

In the event that we are unable to obtain these licenses at a reasonable cost, we and/or current and future collaborators and licensees could encounter delays in product commercialization while we attempt to develop alternative methods or products.

Defense of any lawsuit or failure to obtain any of these licenses could prevent us from commercializing available products.

In addition, unauthorized parties may attempt to steal, copy or otherwise obtain and use our C1 microbial strains, genetic elements, development and manufacturing processes, other technology or products.

Monitoring unauthorized use of our intellectual property is difficult, and we cannot be certain that the steps we have taken will prevent unauthorized use of our technologies, particularly in certain foreign countries where the local laws may not protect our proprietary rights as fully as in the United States.

Moreover, third parties could practice our inventions in territories where we do not have patent protection.

Such third parties may then try to import into the United States or other territories products, or information leading to potentially competing products, made using our inventions in countries where we do not have patent protection for those inventions.

If competitors are able to use our technologies, our ability and our current and future collaborators’ and licensees’ ability to compete effectively could be harmed.

Moreover, others may independently develop and obtain patents for technologies that are similar to or superior to our technologies.

If that happens, we may need to license these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business, financial condition and results of operations.

Confidentiality agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.

We rely in part on trade secret protection to protect our confidential and proprietary information and processes.

However, trade secrets are difficult to protect.

We have taken measures to protect our trade secrets and proprietary information, but these measures may not be effective.

We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting arrangement with us.

These agreements generally require that all confidential information developed by the individual or made known to the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third parties.

These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us shall be our exclusive property.

Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets.

Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

Risks Related to Our Common Stock

The price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.

The trading price of our common stock has been, and is likely to continue to be, volatile.

Biotechnology company stocks generally tend to experience extreme price fluctuations.

The valuations of many biotechnology companies without consistent product sales and earnings are extraordinarily high based on conventional valuation standards such as price-to-earnings and price-to-sales ratios.

These trading prices and valuations may not be sustained.

Factors that may result in fluctuations in our stock price include, but are not limited to, the following:

Changes in the public’s perception of the prospects of biotechnology companies;

Sales of our common stock in the public market by such stockholders or other significant stockholders, executive officers, or directors;

Announcements of new technological innovations, patents or new products or processes by us, Danisco or our current or future collaborators, licensees and competitors;

Announcements by us, Danisco or our collaborators and licensees relating to our relationships with third parties;

Coverage of, or changes in financial estimates by us or securities and industry analysts;

Conditions or trends in the biotechnology industry;

Changes in investor interest in the areas in which we and/or our collaborators and licensees are applying our technologies, such as COVID-19;

Changes in the market valuations of other biotechnology companies;

Limitations or expanded uses in the areas within the biopharmaceutical or other industries into which we can apply our technologies and products;

Actual or anticipated changes in our growth rate relative to our competitors;

Developments in domestic and international governmental policy or regulations;

Announcements by us, Danisco, our current and future collaborators and licensees, or our competitors of significant acquisitions, divestures, strategic partnerships, license agreements, joint ventures or capital commitments;

The position of our cash, cash equivalents and marketable securities;

Any changes in our debt position;

Developments in patent or other proprietary rights held by us, Danisco or by others;

Negative effects related to the stock or business performance of Danisco, our current and future collaborators and licensees, or the abandonment of projects using our technology by our collaborators and/or licensees;

Scientific risks inherent to emerging technologies such as the C1 platform or our other technologies;

Set-backs, and/or failures, and or delays in our or our current and future collaborators’ and licensees’ R&D and commercialization programs;

Delays or failure to receive regulatory approvals by us, Danisco and/or our current and future collaborators and licensees;

Loss or expiration of our or Danisco’s intellectual property rights;

Theft, misappropriation or expiration of owned or licensed proprietary and intellectual property, genetic and biological material owned by us and/or Danisco US, Inc., and VTT Technical Research Centre of Finland Ltd;

Lawsuits initiated by or against us, Danisco, or our current and future collaborators and licensees;

Period-to-period fluctuations in our operating results;

Future royalties from product sales, if any, by Danisco, our current or future strategic partners, collaborators or licensees;

Future royalties may be owed to Danisco by us, our collaborators, licenses, or sub-licensees under certain circumstances related to our Danisco Pharma License;

Short positions taken in our common stock;

Sales of our common stock or other securities in the open market;

There is no assurance that safety, toxicity, pathogenicity, immunogenicity

and other issues will not arise in current or future product development and manufacturing programs due to media, fermentation, inherent

properties or genetic changes in the C1 and other strains and fermentation processes.

these non-therapeutic protein products or other non-pharmaceutical products are not approved by regulators, we or our current and future

customers or collaborators and licensees will not be able to commercialize them, and we may not receive research funding, upfront license

fees, milestone and royalty payments, which are based upon the successful advancement of these products through the drug development

and approval process.

Even after investing significant time and expense, any regulatory approval may also impose limitations on the uses

for which we can market a product, and any marketed product and its manufacturer are subject to continual review.

Discovery of previously

unknown problems with a product or manufacturer may result in new restrictions on the product, manufacturer and manufacturing facility,

including withdrawal of the product from the market.

In certain countries, regulatory agencies also set or approve prices, which may

result in low or unprofitable margins and would have a material adverse effect on our business, financial condition and results of operations.

business is subject to extensive regulation;

failure to comply with these regulations could adversely affect our business and financial

and our collaborators are subject to a wide array of federal, state, local, and international regulations.

These regulations govern,

among other things, research and development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping,

promotion, advertising, distribution, and post-approval monitoring and reporting requirements for pharmaceutical products.

In the United

States, the FDA imposes rigorous requirements for the approval and ongoing regulation of pharmaceutical products, including compliance

with current Good Manufacturing Practices (cGMP).

Similar regulatory regimes exist in other jurisdictions, including the European Medicines

Agency (EMA) and other national authorities.

Any failure to comply with applicable regulatory requirements, or any significant change

in such regulations, could delay or prevent the development, approval or commercialization of our products or product candidates, increase

our costs, or reduce demand for our technologies.

For example, changes in the FDA’s regulation of pharmaceutical products or increased

scrutiny of manufacturing processes could adversely affect our ability or the ability of our collaborators, licensees and customers to

bring products to market or to obtain or maintain product approvals where required.

We may also be subject to FDA or other foreign regulatory

authority inspections, audits or enforcement actions.

Any failure to comply with regulatory requirements or any findings of non-compliance

during regulatory authority inspections could result in warning letters, fines, product recalls, suspension of manufacturing options

or delays in product approvals.

Such actions could materially harm our reputation, business and financial results.

Relating to Intellectual Property

to protect our intellectual property and the intellectual property of certain third parties could harm our competitive position.

success will depend in part on our ability to obtain patents and on our and Danisco’s (as part of the DuPont Transaction, patents

were assigned to Danisco) and our current and future collaborators’, and licensees’ ability to maintain adequate protection

of our and their intellectual property.

If we, Danisco, or our current and future collaborators and licensees do not adequately protect

our intellectual property, competitors may be able to practice our technologies and erode our competitive advantage.

The laws of some

foreign countries do not protect proprietary rights to the same extent as the laws of the United States, and many companies have encountered

significant problems in protecting their proprietary rights in these foreign countries.

the patent positions of biotechnology companies, including our patent position, are generally uncertain and involve complex legal and

factual questions.

We will be able to protect our proprietary rights from unauthorized use by third parties only to the extent that our,

and in certain instances the C1 patents assigned to Danisco, and our current and future collaborators’ and licensees’ proprietary

technologies, are covered by valid and enforceable patents or are effectively maintained as trade secrets.

We intend, from time to time,

to apply for patents covering both our technologies and our products, while at other times, we only maintain such knowledge as trade

secrets without applying for patents, as we deem appropriate.

However, existing and future patent applications may be challenged and

are not guaranteed to result in the issuing of patents.

Even if a patent is obtained, it may not be sufficiently broad to prevent others

from practicing our technologies or from developing competing products.

Others, including Danisco and our current and future collaborators

and licensees, may independently develop similar or alternative technologies or design around our, Danisco’s or our current and

future collaborators’ and licensees’ patented technologies.

In addition, Danisco, our current and future collaborators, licensees,

or other third parties may challenge or invalidate our patents, or our patents may fail to provide us with any competitive advantages.

If any third party is able to gain intellectual property protections for technology similar to our own, they may be successful in blocking

us and our licensees from using the C1 platform or our other technologies and/or commercializing products derived from them.

cannot ensure that any of our pending patent applications will result in issued patents, or even if issued, predict the breadth of the

claims upheld in our and other companies’ patents.

Given that the degree of future protection for our proprietary rights is uncertain,

we cannot ensure that we were the first to invent the inventions covered by our pending patent applications, or that we were the first

to file patent applications for these inventions or the patents we have obtained.

addition, Dyadic will continue to review its existing and potential patent positions and rights.

Based on our analysis if and when the

commercial opportunities and patent enforceability are questionable, we may abandon certain patents in some countries.

There is a risk

that we will abandon potentially valuable patents.

or other proceedings or third-party claims of intellectual property infringement could require us to spend significant time and resources

and could prevent us and our collaborators from commercializing our or their technologies and products or negatively impact our stock

commercial success depends in part on neither infringing patents and proprietary rights of third parties, nor breaching any licenses

that we have entered into with regard to our technologies and products.

Others have filed, and in the future are likely to file, patent

applications covering genes or gene fragments, genetic elements, screening, gene expression and fermentation processes and other intellectual

property that we may wish to utilize with the C1 platform or our other technologies or products and systems that are similar to those

developed with its use.

If these patent applications result in issued patents and we wish to use the claimed technology, we may need

to obtain a license from the appropriate third party.

parties do and may continue to assert that we and/or our current and future collaborators and licensees are employing their proprietary

technology without authorization.

In addition, third parties may obtain patents in the future and claim that use of our technologies

infringes these patents.

We could incur substantial costs and diversion of management and technical personnel in defending ourselves

against any of these claims or enforcing our patents and other intellectual property rights.

Parties making claims against us may be

able to obtain injunctive or other equitable relief, which could effectively block our ability to further develop, commercialize and

sell products, and could result in the award of substantial damages against us.

If a claim of infringement against us is successful,

we may be required to pay damages and obtain one or more licenses from third parties.

In the event that we are unable to obtain these

licenses at a reasonable cost, we and/or current and future collaborators and licensees could encounter delays in product commercialization

while we attempt to develop alternative methods or products.

Defense of any lawsuit or failure to obtain any of these licenses could

prevent us from commercializing available products.

addition, unauthorized parties may attempt to steal, copy or otherwise obtain and use our C1 microbial strains, genetic elements, development

and manufacturing processes, other technology or products.

Monitoring unauthorized use of our intellectual property is difficult, and

we cannot be certain that the steps we have taken will prevent unauthorized use of our technologies, particularly in certain foreign

countries where the local laws may not protect our proprietary rights as fully as in the United States.

Moreover, third parties could

practice our inventions in territories where we do not have patent protection.

Such third parties may then try to import into the United

States or other territories products, or information leading to potentially competing products, made using our inventions in countries

where we do not have patent protection for those inventions.

If competitors are able to use our technologies, our ability and our current

and future collaborators’ and licensees’ ability to compete effectively could be harmed.

Moreover, others may independently

develop and obtain patents for technologies that are similar to or superior to our technologies.

If that happens, we may need to license

these technologies, and we may not be able to obtain licenses on reasonable terms, if at all, which could harm our business, financial

condition and results of operations.

Confidentiality

agreements with employees and others may not adequately prevent disclosures of trade secrets and other proprietary information.

rely in part on trade secret protection to protect our confidential and proprietary information and processes.

However, trade secrets

are difficult to protect.

We have taken measures to protect our trade secrets and proprietary information, but these measures may not

be effective.

We require employees and consultants to execute confidentiality agreements upon the commencement of an employment or consulting

arrangement with us.

These agreements generally require that all confidential information developed by the individual or made known to

the individual by us during the course of the individual’s relationship with us be kept confidential and not disclosed to third

These agreements also generally provide that inventions conceived by the individual in the course of rendering services to us

shall be our exclusive property.

Nevertheless, our proprietary information may be disclosed, third parties could reverse engineer our

biocatalysts and others may independently develop substantially equivalent proprietary information and techniques or otherwise gain access

to our trade secrets.

Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights,

and failure to obtain or maintain trade secret protection could adversely affect our competitive business position.

Related to Our Common Stock

price of our shares of common stock is likely to be volatile, and you could lose all or part of your investment.

trading price of our common stock has been, and is likely to continue to be, volatile.

Biotechnology company stocks generally tend to

experience extreme price fluctuations.

The valuations of many biotechnology companies without consistent product sales and earnings are

extraordinarily high based on conventional valuation standards such as price-to-earnings and price-to-sales ratios.

These trading prices

and valuations may not be sustained.

Factors that may result in fluctuations in our stock price include, but are not limited to, the

Changes in the public’s

perception of the prospects of biotechnology companies;

The public’s perception

of non-therapeutic interventions;

Sales of our common stock

in the public market by such stockholders or other significant stockholders, executive officers, or directors;

Announcements of new technological

innovations, patents or new products or processes by us, Danisco or our current or future collaborators, licensees and competitors;

Announcements by us, Danisco

or our collaborators and licensees relating to our relationships with third parties;

Coverage of, or changes

in financial estimates by us or securities and industry analysts;

Conditions or trends in

the biotechnology industry;

Changes in investor interest

in the areas in which we and/or our collaborators and licensees are applying our technologies;

Access to outside research

Changes in the market valuations

of other biotechnology companies;

Limitations or expanded

uses in the areas within the biopharmaceutical or other industries into which we can apply our technologies and products;

Actual or anticipated changes

in our growth rate relative to our new potential competitors;

Developments in domestic

and international governmental policy or regulations;

Announcements by us, Danisco,

our current and future collaborators and licensees, or our competitors of significant acquisitions, divestures, strategic partnerships,

license agreements, joint ventures or capital commitments;

The position of our cash,

cash equivalents and marketable securities;

Any changes in our debt

position as a result, in part, of our business transition;

Developments in patent

or other proprietary rights held by us, Danisco or by others;

Negative effects related

to the stock or business performance of Danisco, our current and future collaborators and licensees, or the abandonment of projects

using our technology by our collaborators and/or licensees;

Scientific risks inherent

to emerging technologies such as the C1 platform or our other technologies;

Set-backs, and/or failures,

and or delays in our or our current and future collaborators’ and licensees’ R&D and commercialization programs;

Delays or failure to receive

regulatory approvals by us, Danisco and/or our current and future collaborators and licensees;

Loss or expiration of our

or Danisco’s intellectual property rights;

Theft, misappropriation

or expiration of owned or licensed proprietary and intellectual property, genetic and biological material owned by us and/or Danisco

US, Inc., and VTT Technical Research Centre of Finland Ltd;

Our inability to acquire

new intellectual property, genetic and biological material owned by us and/or Danisco;

Unanticipated risks as

a result of our business transition;

Lawsuits initiated by or

against us, Danisco, or our current and future collaborators and licensees;

Period-to-period fluctuations

in our operating results;

Future royalties from product

sales, if any, by Danisco, our current or future strategic partners, collaborators or licensees;

Future royalties may be

owed to Danisco by us, our collaborators, licenses, or sub-licensees under certain circumstances related to our Danisco Pharma License;

Short positions taken in

our common stock;

Sales of our common stock

or other securities in the open market;

Stock buy-back programs;

Stock splits; and

Decisions made by the board related to potential registration of Dyadic’s stock under the Securities Act of 1933, as amended (the “Securities Act”), and/or up listing to another stock exchange.

If we were to become party to a securities class action suit, we could incur substantial legal fees and our management’s attention and resources could be diverted from operating our business to responding to litigation.

Our quarterly and annual operating results may be volatile.

Our quarterly and annual operating results have fluctuated in the past and are likely to do so in the future.

These fluctuations could cause our stock price to vary significantly or decline.

Stock splits;

Decisions made by the board

related to potential registration of Dyadic’s stock under the Securities Act of 1933, as amended (the “Securities Act”),

and/or up listing to another stock exchange.

we were to become party to a securities class action suit, we could incur substantial legal fees and our management’s attention

and resources could be diverted from operating our business to responding to litigation.

quarterly and annual operating results may be volatile.

quarterly and annual operating results have fluctuated in the past and are likely to do so in the future.

These fluctuations could cause

our stock price to vary significantly or decline.

Some of the factors that could impact our operating results include:

Expiration of or cancellations of our research contracts with current and future collaborators and/or licensees, which may not be renewed or replaced;

Setbacks or failures in our and our current and future collaborators’ and licensees’ research, development and commercialization efforts;

Setbacks, or delays in our research and development efforts to develop and produce biologics;

Setbacks, or delays in our research and development efforts to re-engineer the C1 platform or our other technologies for their applications and use in developing and producing biologics;

The speed, and success rate of our discovery and research and development efforts leading to potential licenses, or other forms of collaborations, access fees, milestones and royalties;

The timing and willingness of current and future collaborators and licensees to utilize C1 to develop and commercialize their products which would result in potential upfront fees, milestones and royalties;

General and industry specific economic conditions, which may affect our current and future collaborators’ and licensees’ R&D expenditures;

The adoption and acceptance of the C1 platform and our other technologies by biopharmaceutical and non-pharmaceutical companies and regulatory agencies;

The addition or loss of one or more of the collaborative partners, grants, research funding, or licensees we are working with to further develop and commercialize our technologies and products in the pharmaceutical industry;

Our ability to file, maintain and defend our intellectual property and to protect our proprietary information and trade secrets;

Our ability to develop technology, products and processes that do not infringe on the intellectual property of third parties;

The improvement and advances made by our competitors to CHO, E.coli , yeast, inset cells, plant and other expression systems;

The introduction by our competitors of new discovery and expression technologies competitive with the C1 platform;

Our ability to enter into new research projects, grants, licenses or other forms of collaborations and generate revenue from such parties;

Scientific risk associated with emerging technologies such as the C1 platform;

Failure to bring on the necessary research and manufacturing capacity, e.g., CRO, CMO (contract manufacturing organization), and CDMO (contract development and manufacturing organization), if required;

Uncertainty regarding the timing of research funding, grants or upfront license fees for new C1 platform, our other technologies, collaborations, license agreements or expanded license agreements; and

Delays or failure to receive upfront fees, milestones and royalties and other payments.

Due to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results are not necessarily a good indication of our future performance.

Our operating results in some quarters, or even in some years, may not meet the expectations of stock market analysts and investors, potentially causing our stock price to decline.

We do not expect to pay cash dividends in the future.

We have never paid cash dividends on our stock and do not anticipate paying any dividends for the foreseeable future.

The payment of dividends on our stock, if ever, will depend on our earnings, financial condition and other business and economic factors deemed relevant for consideration by our board of directors.

If we do not pay dividends, our stock may be less valuable because a return on investment will only occur if and to the extent that our stock price appreciates.

Our anti-takeover defense provisions may deter potential acquirers and depress our stock price.

Certain provisions of our certificate of incorporation, bylaws and Delaware law, as well as certain agreements we have with our executives, could make it substantially more difficult for a third party to acquire control of us.

Expiration of or cancellations

of our research contracts with current and future collaborators and/or licensees, which may not be renewed or replaced;

Setbacks or failures in

our and our current and future collaborators’ and licensees’ research, development and commercialization efforts;

Setbacks, or delays in

our research and development efforts to develop and produce biologics;

Setbacks, or delays in

our research and development efforts to re-engineer the C1 platform or our other technologies for their applications and use in developing

and producing biologics;

The speed, and success

rate of our discovery and research and development efforts leading to potential licenses, or other forms of collaborations, access

fees, milestones and royalties;

The timing and willingness

of current and future collaborators and licensees to utilize C1 to develop and commercialize their products which would result in

potential upfront fees, milestones and royalties;

General and industry specific

economic conditions, which may affect our current and future collaborators’ and licensees’ R&D expenditures;

The adoption and acceptance

of the C1 platform and our other technologies by biopharmaceutical and non-pharmaceutical companies and regulatory agencies;

The addition or loss of

one or more of the collaborative partners, grants, research funding, or licensees we are working with to further develop and commercialize

our technologies and products in the pharmaceutical industry;

Our ability to file, maintain

and defend our intellectual property and to protect our proprietary information and trade secrets;

Our ability to develop

technology, products and processes that do not infringe on the intellectual property of third parties;

The improvement and advances

made by our competitors to CHO, E.coli , yeast, inset cells, plant and other expression systems;

The introduction by our

competitors of new discovery and expression technologies competitive with the C1 platform;

Our ability to enter into

new research projects, grants, licenses or other forms of collaborations and generate revenue from such parties;

Scientific risk associated

with emerging technologies such as the C1 platform;

to bring on the necessary research and manufacturing capacity, e.g., CRO, CMO (contract manufacturing organization), and CDMO (contract

development and manufacturing organization), if required;

Uncertainty regarding the

timing of research funding, grants or upfront license fees for new C1 platform, our other technologies, collaborations, license agreements

or expanded license agreements;

Delays or failure to receive

upfront fees, milestones and royalties and other payments.

to the possibility of fluctuations in our revenues and expenses, we believe that quarter-to-quarter comparisons of our operating results

are not necessarily a good indication of our future performance.

Our operating results in some quarters, or even in some years, may not

meet the expectations of stock market analysts and investors, potentially causing our stock price to decline.

do not expect to pay cash dividends in the future.

have never paid cash dividends on our stock and do not anticipate paying any dividends for the foreseeable future.

The payment of dividends

on our stock, if ever, will depend on our earnings, financial condition and other business and economic factors deemed relevant for consideration

by our board of directors.

If we do not pay dividends, our stock may be less valuable because a return on investment will only occur

if and to the extent that our stock price appreciates.

anti-takeover defense provisions may deter potential acquirers and depress our stock price.

provisions of our certificate of incorporation, bylaws and Delaware law, as well as certain agreements we have with our executives, could

make it substantially more difficult for a third party to acquire control of us.

These provisions include the following:

We may issue preferred stock with rights senior to those of our common stock;

We have a classified board of directors;

Action by written consent by stockholders is not permitted;

Our board of directors has the exclusive right to fill vacancies and set the number of directors;

Cumulative voting by our stockholders is not allowed; and

We require advance notice for nomination of directors by our stockholders and for stockholder proposals.

These provisions may discourage certain types of transactions involving an actual or potential change in control.

These provisions may also limit our stockholders’ ability to approve transactions that they may deem to be in their best interests and discourage transactions in which our stockholders might otherwise receive a premium for their stock over the current market price.

Concentration of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant corporate decisions and depress our stock price.

Our executive officers, directors and principal stockholders (5% stockholders) together control approximately 34.7% of our 29,835,799 shares of outstanding common stock as of December 31, 2024.

Our Founder and Chief Executive Officer Mark Emalfarb, through the Mark A.

Emalfarb Trust U/A/D October 1, 1987, as amended (the “MAE Trust”) of which he is the trustee and beneficiary, owned approximately 15.6% of our outstanding common stock as of December 31, 2024.

Further, the Francisco Trust U/A/D February 28, 1996 (the “Francisco Trust”), whose beneficiaries are the descendants and spouse of Mr.

We may issue preferred

stock with rights senior to those of our common stock;

We have a classified board

of directors;

Action by written consent

by stockholders is not permitted;

Our board of directors

has the exclusive right to fill vacancies and set the number of directors;

Cumulative voting by our

stockholders is not allowed;

We require advance notice

for nomination of directors by our stockholders and for stockholder proposals.

provisions may discourage certain types of transactions involving an actual or potential change in control.

These provisions may also

limit our stockholders’ ability to approve transactions that they may deem to be in their best interests and discourage transactions

in which our stockholders might otherwise receive a premium for their stock over the current market price.

Concentration

of ownership among our existing officers, directors and principal stockholders may prevent other stockholders from influencing significant

corporate decisions and depress our stock price.

executive officers, directors and principal stockholders (5% stockholders) together control approximately 24.2% of our 36,187,798 shares

of outstanding common stock as of December 31, 2025.

Founder and Chief Executive Officer Mark Emalfarb, through the Mark A.

Emalfarb Trust U/A/D October 1, 1987, as amended (the “MAE

Trust”) of which he is the trustee and beneficiary, owned approximately 13.1% of our outstanding common stock as of December 31,

Further, the Francisco Trust U/A/D February 28, 1996 (the “Francisco Trust”), whose beneficiaries are the descendants

and spouse of Mr.

Emalfarb, owned approximately 9.4% of our outstanding common stock as of December 31, 2025.

We have historically been partially controlled, managed and partially funded by Mr.

We have historically been

partially controlled, managed and partially funded by Mr.

Emalfarb, and affiliates of Mr.

Collectively, Mr.

Emalfarb and stockholders affiliated with Mr.

Emalfarb and stockholders

affiliated with Mr.

Emalfarb controlled approximately 22.5% of our outstanding common stock as of December 31, 2025.

Emalfarb may be able to control or significantly influence all matters requiring approval by our stockholders, including the election of directors and the approval of mergers or other business combination transactions.

Emalfarb may be able to control or significantly influence all matters requiring approval by our stockholders, including the election

of directors and the approval of mergers or other business combination transactions.

The interests of Mr.

Emalfarb may not always coincide with the interests of other stockholders, and he may take actions that advance his personal interests and are contrary to the desires of our other stockholders.

If our existing officers, directors and principal stockholders act together, they will be able to exert a significant degree of influence over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of significant corporate transactions.

In addition, this concentration of ownership may delay or prevent a change in control and might affect the market price of our stock, even when a change may be in the best interests of all stockholders.

Certain of our principal stockholders may elect to increase their holdings of our common stock, which may have the impact of delaying or preventing a change of control.

Moreover, the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and, accordingly, they could cause us to enter into transactions or agreements, which we would not otherwise consider.

Future resales of shares of our common stock may negatively affect our stock price.

The resale of shares of our common stock, or the perception that such resales could occur, could harm the prevailing market price of shares of our common stock.

These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate.

As of December 31, 2024, there were 29,835,799 shares of our common stock outstanding.

Approximately 34.7% of these outstanding common shares are beneficially owned or controlled by our executive officers, directors and principal stockholders.

Our common stock has a relatively small public float.

As a result, sales of substantial amounts of shares of our common stock, or even the potential for such sales, may materially and adversely affect prevailing market prices for our common stock.

In addition, any adverse effect on the market price of our common stock could make it difficult for us to raise additional capital through sales of equity securities.

The Company is exposed to credit risk and fluctuations in the values of its investment portfolio.

The Company’s investments can be negatively affected by liquidity, credit deterioration, financial results, market and economic conditions, political risk, sovereign risk, interest rate fluctuations or other factors.

As a result, the value and liquidity of the Company’s cash, cash equivalents, and marketable and non-marketable securities may fluctuate substantially, which could result in significant losses and could have a material adverse impact on the Company’s financial condition and operating results.

We are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors.

We are a smaller reporting company and are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information.

We are also exempt from the requirement to obtain an external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley Act.

These exemptions and reduced disclosures in our filings with the Securities and Exchange Commission due to our status as a smaller reporting company mean our auditors do not review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions.

If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock, and our stock prices may be more volatile.

If securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research or reports regarding us, our business or our market, our stock price and trading volume could decline.

The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us, our business or our market .

Emalfarb may not always coincide

with the interests of other stockholders, and he may take actions that advance his personal interests and are contrary to the desires

of our other stockholders.

our existing officers, directors and principal stockholders act together, they will be able to exert a significant degree of influence

over our management and affairs and over matters requiring stockholder approval, including the election of directors and approval of

significant corporate transactions.

In addition, this concentration of ownership may delay or prevent a change in control and might affect

the market price of our stock, even when a change may be in the best interests of all stockholders.

Certain of our principal stockholders

may elect to increase their holdings of our common stock, which may have the impact of delaying or preventing a change of control.

the interests of this concentration of ownership may not always coincide with our interests or the interests of other stockholders, and,

accordingly, they could cause us to enter into transactions or agreements, which we would not otherwise consider.

resales of shares of our common stock may negatively affect our stock price.

resale of shares of our common stock, or the perception that such resales could occur, could harm the prevailing market price of shares

of our common stock.

These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell equity

securities in the future at a time and at a price that we deem appropriate.

of December 31, 2025, there were 36,187,798 shares of our common stock outstanding.

Approximately 24.2% of these outstanding common shares

are beneficially owned or controlled by our executive officers, directors and principal stockholders.

common stock has a relatively small public float.

As a result, sales of substantial amounts of shares of our common stock, or even the

potential for such sales, may materially and adversely affect prevailing market prices for our common stock.

In addition, any adverse

effect on the market price of our common stock could make it difficult for us to raise additional capital through sales of equity securities.

Company is exposed to credit risk and fluctuations in the values of its investment portfolio.

Company’s investments can be negatively affected by liquidity, credit deterioration, financial results, market and economic conditions,

political risk, sovereign risk, interest rate fluctuations, tariffs or other trade restrictions, or other factors.

As a result, the value

and liquidity of the Company’s cash, cash equivalents, and marketable and non-marketable securities may fluctuate substantially,

which could result in significant losses and could have a material adverse impact on the Company’s financial condition and operating

are a smaller reporting company, and the reduced disclosure requirements applicable to smaller reporting companies may make our common

stock less attractive to investors.

are a smaller reporting company and are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption

from providing selected financial data and executive compensation information.

We are also exempt from the requirement to obtain an

external audit on the effectiveness of internal control over financial reporting provided in Section 404(b) of the Sarbanes-Oxley

These exemptions and reduced disclosures in our filings with the SEC due to

our status as a smaller reporting company mean our auditors do not review our internal control over financial reporting and may make

it harder for investors to analyze our results of operations and financial prospects.

We cannot predict if investors will find our

common stock less attractive because we may rely on these exemptions.

If some investors find our common stock less attractive as a

result, there may be a less active trading market for our common stock, and our stock prices may be more volatile.

securities or industry analysts do not publish research or reports about our business, or if they issue adverse or misleading research

or reports regarding us, our business or our market, our stock price and trading volume could decline.

trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us,

our business or our market.

We currently have two securities analysts publishing research about our stock.

I f no or few securities or industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted.

If any of the analysts who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline.

If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

If no or few securities or

industry analysts commence or maintain coverage of us, the trading price for our stock would be negatively impacted.

If any of the analysts

who cover us issue adverse or misleading research or reports regarding us, our business model, our intellectual property, our stock performance

or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline.

more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets,

which in turn could cause our stock price or trading volume to decline.

we fail to comply with listing standards of the Nasdaq Stock Market LLC (“Nasdaq”), our common stock may be delisted, adversely

affecting the liquidity and market price of our common stock, as well as our ability to obtain sufficient additional capital to fund

our operations and to continue to operate as a going concern.

common stock is currently listed on the Nasdaq Capital Market, which has minimum requirements that a company must meet in order to remain

These requirements include maintaining a minimum bid price of our common stock, which cannot fall below $1.00 for a period of

more than 30 consecutive trading days (the “Minimum Bid Price Requirement”).

On December 19, 2025, we received a deficiency

notice from the Staff of Nasdaq notifying us that for the last 30 consecutive business days our securities had not maintained the minimum

bid price of at least $1.00 per share required by the continued listing requirements of Nasdaq Listing Rule 5550(a)(2).

The Minimum Bid

Price Notice had no immediate effect on the listing of our common stock on the Nasdaq Capital Market.

In accordance with Nasdaq Listing

Rule 5810(c)(3)(A), we have 180 calendar days, or until June 17, 2026 (the “Minimum Bid Price Compliance Date”), to regain

compliance with the minimum bid price requirement by having our bid price close at $.001 per share or more for a minimum of 10 consecutive

business days before the Minimum Bid Price Compliance Date (subject to the Staff’s discretion to extend this period an additional

180-day period, provided that on the Minimum Bid Price Compliance Date, we meet the applicable market value of publicly held shares requirement

for continued listing and all other applicable standards for initial listing on the Nasdaq Capital Market).

There can be no assurance

that we will be granted an extension.

we do not regain compliance by the Minimum Bid Price Compliance Date or any extension date, the Staff will provide written notification

that our common stock is subject to delisting.

At that time, we may appeal the delisting determination to a hearings panel pursuant to

the procedures set forth in the applicable Nasdaq listing rules.

However, there can be no assurance that, if we receive a delisting notice

and appeal the delisting determination by Nasdaq to the panel, such appeal would be successful.

If our common stock is in turn delisted

from Nasdaq as a result of our failure to comply with the Minimum Bid Price Requirement or any other requirement for continued listing

on Nasdaq, trading of our common stock could be conducted in the over-the-counter market established for unlisted securities such as

the OTCQX, the OTCQB, the OTCID Basic Market or the Pink Limited Market, but there can be no assurance that our common stock will be

eligible for trading on any such alternative market.

Additionally, the liquidity of our common stock would be adversely affected, the

market price of our common stock could decrease, our ability to obtain sufficient additional capital to fund our operations and to continue

to operate as a going concern would be substantially impaired and transactions in our common stock could lose federal preemption of state

securities laws.

Furthermore, there could be a reduction in our coverage by securities analysts, and broker-dealers may be deterred from

making a market in or otherwise seeking or generating interest in our common stock, which could cause the price of our common stock to

decline further.

Moreover, delisting may also negatively affect our collaborators’, vendors’, suppliers’ and employees’

confidence in us and employee morale.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 1A. Risk Factors